Immobilized biological entities
Covalently attaching heparin fragments of 5 to 18 sugar units with polysaccharide sequence A to medical device surfaces synergistically inhibits both FIIa and FXa, addressing inefficiencies in traditional heparin attachment methods and enhancing anticoagulant properties.
Patent Information
- Application Number
- JP2021518659
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-03
- Filing Date
- 2019-10-03
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2039-10-03
AI Technical Summary
Existing medical devices face issues with blood clotting and inflammation due to interactions with blood, and traditional methods of attaching heparin to surfaces to prevent thrombosis are inefficient in inhibiting certain clotting factors, particularly Factor IIa (FIIa) when using heparin fragments smaller than 18 sugar units.
Covalently attaching heparin fragments of 5 to 18 sugar units to a surface, ensuring at least a portion contains the polysaccharide sequence A, enhances the surface's ability to inhibit both Factor IIa and Factor Xa (FIIa and FXa) through synergistic interactions when immobilized, overcoming the limitations of smaller fragments in solution.
The immobilized heparin fragments effectively inhibit both FIIa and FXa, providing enhanced anticoagulant activity, increased stability, and improved biocompatibility, while maintaining a uniform distribution and predictable activity.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to surfaces having multiple heparin fragments covalently attached thereto, solid objects comprising such surfaces, and processes for preparing such surfaces. In particular, the present invention relates to surfaces having multiple heparin fragments covalently attached thereto, which catalyze the inhibition of FIIa and FXa by AT. [Background technology]
[0002] BACKGROUND OF THEINVENTION When a medical device is implanted in the body or comes into contact with bodily fluids, several different reactions are initiated, some of which result in inflammation and some of which result in clotting of blood in contact with the device surface. To combat these serious adverse effects, heparin, a well-known anticoagulant compound, has traditionally been administered systemically to patients before the medical device is implanted in the body or when it comes into contact with its bodily fluids to provide an antithrombotic effect.
[0003] One of the most successful processes for rendering medical devices non-thrombogenic is the covalent attachment of heparin to the modified surface of the device. The general method and its improvements are described in European Patents: EP-B-0086186, EP-B-0086187, EP-B-0495820, and US 6,461,665 (incorporated herein by reference).
[0004] These patents firstly describe the preparation of surface-modified substrates by selective cleavage of heparin polysaccharide chains, for example using nitrous acid decomposition, which results in the formation of terminal aldehyde groups. Secondly, the introduction of one or more surface-modifying layers carrying primary amino groups to the surface of the medical device, and then reacting the aldehyde groups on the polysaccharide chains with the amino groups on the surface-modifying layer, followed by reduction of the intermediate Schiff base to form stable secondary amine bonds.
[0005] Factor IIa (also known as thrombin, "FIIa") and factor Xa ("FXa") are two of several clotting factors that all act together to result in the formation of blood clots on surfaces in contact with blood. Antithrombin (also known as antithrombin III, "ATIII", or "AT") is the most important endogenous coagulation inhibitor. It neutralizes the action of FIIa, FXa, and other coagulation factors, thus limiting or restricting blood clotting. The ability of heparin to catalyze the inhibition of activated coagulation factors such as FIIa and FXa by antithrombin (AT) depends on a specific pentasaccharide structure depicted in FIG. 1, called the activation sequence (also referred to herein as the "active pentasaccharide sequence" or "pentasaccharide sequence A"). AT binds to the activation sequence of heparin, resulting in a conformational change in AT that accelerates the inhibition of the coagulation factors. However, the inhibition mechanism catalyzed by heparin differs between FIIa and FXa. Inhibition of FXa by AT is catalyzed by heparin fragments of pentasaccharide (five sugar units) or greater in size that contain the active sequence. However, since AT and FIIa are required to bind to the same heparin chain in a triple-bridge complex (Petitou, M. and van Boeckel CAA, Angew. Chem. Int. Ed. 2004, 43, 3118-3133), the mechanism of inhibition of FIIa requires heparin fragments of a minimum size of 18 sugar units to achieve detectable inhibition (Lane DA et al., Biochem J (1984) 218, 725-732). However, the level of inhibition achieved by 18 sugar unit fragments is still very low. To achieve substantial inhibition of FIIa, the fragments must then contain more than 18 sugar units. Thus, the prior art teaches that heparin fragments containing the active sequence but containing 18 or fewer saccharide units have inhibitory potential for FXa but low or no inhibitory potential for FIIa.
[0006] WO 91 / 15252 discloses the incorporation of oligosaccharides derived from heparin into the backbone of a polymer which can then be applied to a surface. This approach differs from that of the present invention, in which heparin fragments are covalently attached or conjugated to a surface. Summary of the Invention
[0007] (Summary of the invention) The inventors have surprisingly discovered that fragments of heparin that lack the ability to catalyze the inhibition of FIIa by AT in solution can catalyze this same reaction when immobilized on a surface. The immobilized fragments are organized in a manner that may enable them to act synergistically to achieve what would require much longer molecules in solution.
[0008] According to one aspect of the invention, there is provided an anticoagulant surface, the surface having a plurality of heparin fragments covalently attached thereto, wherein the fragments consist of 5 to 18 saccharide units, and at least a portion of the plurality of fragments have the polysaccharide sequence A: [ka] (Wherein, R=Ac or SO3 - is) Including, This surface catalyzes the inhibition of FIIa and FXa by AT (hereinafter "surface according to the invention" or "surface of the invention").
[0009] The surfaces of the present invention, in at least some embodiments, may have one or more of the following advantages. (i) Inhibition of FIIa; (ii) inhibition of FXa; (iii) increased anticoagulant activity of the heparin fragments when immobilized; (iv) increased ease of production; (v) increased suitability for coating solid objects; (vi) increasing embedding suitability; (vii) increased stability; (viii) use of heparin fragments; (ix) Use of non-animal origin materials; (x) biocompatibility, e.g., increased hemocompatibility; (xi) Increased blood contact performance
[0010] Additionally, at least some of the embodiments of the present invention may have one or more of the following advantages. (a) Heparin fragments of synthetically feasible size, i.e., less than 18 sugar units, can be utilized in FIIa- and FXa-inhibitory coatings; (b) anticoagulant coatings that inhibit both FIIa and Fxa can be obtained from non-animal derived heparin fragments; (c) a coating having enhanced inhibitory activity against FIIa can be obtained; (d) immobilized heparin fragments from synthetic sources can produce coatings with a defined mechanism of action or more predictable activity by controlling and precisely quantitating the amount of polysaccharide sequence A present; (e) a coating can be obtained that has high anticoagulant activity, such as heparin activity, as determined, for example, using Evaluation Method J; (f) due to its covalent binding, an anticoagulant coating can be obtained that does not leach heparin fragments and therefore remains active for extended periods of time; (g) A coating of heparin fragments can be obtained that has a uniform distribution and is relatively smooth, for example, as determined using Evaluation Method I. [Brief description of the drawings]
[0011] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1] Heparin active sequence (A) [Diagram 2] Schematic diagram of the preparation of oligosaccharide fractions from sodium heparin. [Diagram 3] Surface-immobilized heparin fragments obtained from nitrous acid digestion [Figure 4]Fondaparinux sodium / Arixtra®, a synthetically produced anticoagulant [Diagram 5] Retrosynthetic scheme for a pentasaccharide with a linker synthetically incorporated at the reducing end [Figure 6] A synthetic pentasaccharide with a linker at the C1 position of the reducing end that contains a functional group allowing immobilization [Figure 7] Analytical chromatography of isolated oligosaccharide fractions [Figure 8] Toluidine blue staining of coated PVC [Figure 9] Retrosynthetic scheme for a pentasaccharide with a synthetically incorporated linker at the non-reducing end DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] Detailed Description of the Invention (Heparin and its fragments) Heparin is a member of the glycosaminoglycan family of carbohydrates and consists of repeating disaccharide units that are variably sulfated. Heparin and its fragments are composed of alternating hexuronic acid and D-glucosamine units. The hexuronic acid units consist of D-glucuronic acid and L-iduronic acid, which are β- and α-(1,4)-linked to the glucosamine units, respectively. The majority of the L-iduronic acid residues are O-sulfated at the 2-position. The D-glucosamine units are N-sulfated, O-sulfated at the 6-position, and α-(1,4)-linked to the hexuronic acid residues. Some D-glucosamine units are also O-sulfated at the 3-position.
[0013] The anticoagulant activity of heparin is primarily due to the AT binding sequence of Figure 1, which is present in only about one-third of the heparin chains that make up heparin utilized in hospitals.
[0014] Fragments of heparin can be derived from full length heparin (native heparin) or any variant of heparin. Particularly suitable variants of heparin from which the fragments can be derived include alkali metal or alkaline earth metal salts of heparin (e.g., sodium heparin (e.g., Hepsal or Pularin), potassium heparin (e.g., Clarin), lithium heparin, calcium heparin (e.g., Calciparine), or magnesium heparin (e.g., Cutheparine)), low molecular weight heparins (e.g., ardeparin sodium, tinzaparin, or dalteparin), heparan sulfate, heparinoids, heparin-based compounds, heparins with hydrophobic counterions, synthetic heparin compositions capable of antithrombin-mediated FXa inhibition, synthetic heparin derivatives that contain at least the active pentasaccharide sequence from heparin (e.g., Petitou et al., Biochimie, 2003, 85(1-2):83-9), such as heparin modified by mild nitrous acid degradation (US 4,613,665 A, incorporated herein by reference in its entirety) or periodate oxidation (US 6,653,457 B1, incorporated herein by reference in its entirety).
[0015] In some embodiments, all of the heparin fragments contain the active pentasaccharide sequence. In other embodiments, only a small proportion of the heparin fragments contain the active pentasaccharide sequence. In the case of heparin fragments produced by fragmentation methods, a relatively low percentage of the active pentasaccharide sequence may be present. Preferably, at least 1%, more preferably at least 5%, more preferably at least 10%, more preferably at least 15%, more preferably at least 20%, and more preferably at least 30% of the heparin fragments contain the active pentasaccharide sequence. In the case of heparin fragments produced by synthetic means, a higher percentage of the active pentasaccharide sequence may be present. Preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, and more preferably at least 99% of the heparin fragments contain the active pentasaccharide sequence.
[0016] In such embodiments, the concentration of fragments containing active sequences can be increased by, for example, purification on an AT-binding affinity column.
[0017] In some embodiments, the heparin fragments are structurally homogeneous (i.e., the heparin fragments are substantially identical, more preferably identical) and all contain polysaccharide sequence A. In other embodiments, the heparin fragments are structurally heterogeneous (i.e., the heparin fragments are included in a mixture, where the mixture includes at least two different heparin fragments). When the heparin fragments are structurally heterogeneous, in one embodiment, only a small proportion of the heparin fragments contain the active pentasaccharide sequence as described above. In a more preferred embodiment, the heparin fragments are structurally heterogeneous and all contain polysaccharide sequence A.
[0018] Fragments of heparin can be produced using techniques known in the art. Preferably, the fragments are fragments of native heparin produced by a process involving degradation (e.g., fragmentation) of native heparin. As shown in the examples below, fragments of heparin can be prepared by partial nitrous acid cleavage of native heparin, optionally followed by fragmentation by gel chromatography.
[0019] Alternatively, fragments of heparin can be produced synthetically, which can be accomplished by chemical, enzymatic or organic chemical methods, such as those detailed in the Examples.
[0020] According to the present invention, the fragment consists of 5 to 18 sugar units. Preferably, the fragment consists of at least 6 sugar units, more preferably at least 7, more preferably at least 8 sugar units. Preferably, the fragment consists of 17 sugar units or less, more preferably 16 sugar units or less, more preferably 15 sugar units or less, more preferably 14 sugar units or less, more preferably 13 sugar units or less, more preferably 12 sugar units or less, more preferably 11 sugar units or less, more preferably 10 sugar units or less, more preferably 9 sugar units or less, more preferably 8 sugar units or less. In one embodiment, the fragment consists of 5 sugar units. In one embodiment, the fragment consists of 5 to 18, such as 5 to 17, such as 5 to 16, such as 5 to 15, such as 5 to 10, such as 5 to 8 sugar units. In another embodiment the fragment consists of 6 to 18, such as 6 to 17, for example 6 to 16, such as 6 to 15, for example 6 to 10, for example 6 to 8 sugar units.
[0021] Fragments of heparin can be produced by nitrous acid cleavage. In fact, the octasaccharide is the shortest fragment that can contain a functional active sequence when produced by nitrous acid cleavage (Thunberg L. et al., FEBS Letters 117 (1980), 203-206), because the decomposition by diazotization to form a free terminal aldehyde group consumes one of the four D-glucosamine units. The remaining D-glucosamines, if they have the correct sulfation pattern, become part of the active AT-binding sequence. See FIG. 1. In fact, only a small proportion of the octasaccharide fragments contain the active sequence, because the majority of the heparins from which they are made lack the active sequence.
[0022] (Immobilization of heparin fragments) The heparin fragments can be covalently attached to a surface using techniques known in the art. As shown in the examples below, the heparin fragments can be attached to a surface having an outermost layer of polyamines, for example, via reductive amination (see, for example, Larm et al. in EP0086186A1 and EP0495820B1). The heparin fragments can be covalently attached to a surface, and therefore, the heparin fragments do not significantly dissolve or leach from the surface.
[0023] Preferably, the heparin fragment is single-point bonded, more preferably terminal-point bonded. More preferably, the heparin fragment is covalently bonded to the surface via its reducing end, more preferably, the heparin fragment is covalently bonded to the surface via position C1 of its reducing end. See Figure 6. The advantage of terminal-point bond, especially reducing end-point bond, is that the biological activity of the heparin fragment is maximized due to enhanced availability of antithrombin interaction sites compared to bond at other locations in the heparin fragment.
[0024] A representative end-point attachment process is described in EP 0086186 B1 (Larm, incorporated herein by reference in its entirety), which discloses a process for the covalent attachment of oligomeric or polymeric organic materials to various types of substrates containing primary amino groups. The material to be coupled, which may be heparin, is subjected to decomposition by diazotization to form a material fragment having a free terminal aldehyde group. This material fragment is then reacted through its aldehyde group with the amino group of the material to form a Schiff base, which is then converted (by reduction) to a secondary amine.
[0025] WO 91 / 15252 discloses the incorporation of oligosaccharides derived from heparin into the backbone of a polymer which can then be applied to a surface. This approach differs from that of the present invention, in which heparin fragments are covalently bound or conjugated to a surface (see page 5, second paragraph of WO 91 / 15252).
[0026] Preferably, the surfaces of the invention comprise pendant functional groups to which fragments of heparin are covalently attached. Preferably, the fragments of heparin are covalently attached or conjugated to the surface (preferably via modified reducing end residues).
[0027] Preferably, no heparin fragments are incorporated into the surface. Preferably, no heparin fragments are incorporated into a polymer backbone, particularly a polymer backbone comprising acrylamide. Preferably, the surface does not comprise a copolymer, particularly a copolymer comprising heparin fragments, more particularly a copolymer comprising heparin and acrylamide fragments. Preferably, the surface of the invention is not produced by incorporation of heparin fragments into a polymer backbone. Preferably, the surface is not a polymer disclosed in WO 91 / 15252.
[0028] The antithrombotic properties of the surfaces of the invention can be enhanced by increasing the heparin fragment density. In particular, inhibition of FIIa (e.g., as determined by Evaluation Method H) can be enhanced by increasing the heparin density. Thus, preferably, the surfaces according to the invention have a heparin density of at least 1 μg / cm2, preferably measured according to Evaluation Method H. 2 , e.g., at least 2 μg / cm 2 , at least 4 μg / cm 2 , at least 5 μg / cm 2 , or at least 6 μg / cm 2 has a heparin fragment concentration of
[0029] In one embodiment, a method of making an anticoagulant surface is provided comprising covalently attaching to a surface a plurality of fragments of heparin, wherein the fragments consist of 5 to 18 saccharide units, and at least a portion of the plurality of fragments has the polysaccharide sequence A: [ka] (Wherein, R=Ac or SO3 - is) Including, This surface catalyzes the inhibition of FIIa and FXa.
[0030] Preferably, the surface is a solid surface.
[0031] In one embodiment, an anticoagulant surface is provided, obtained by covalently attaching a plurality of fragments of heparin to a surface, wherein the fragments consist of 5 to 18 saccharide units and at least a portion of the plurality of fragments has the polysaccharide sequence A: [ka] (Wherein, R=Ac or SO3 - is) Including, This surface catalyzes the inhibition of FIIa and FXa by AT.
[0032] Preferably, the surface is a solid surface.
[0033] (Linkers and Spacers) (Linker) In one embodiment, the heparin fragment can be covalently attached to the surface via a linker, which facilitates the covalent attachment of the heparin fragment to the surface.
[0034] Preferably, the linker does not interfere with the heparin activity (ie, AT binding) of the heparin fragment.
[0035] In one embodiment, the linker is comprised of an alkylene chain, which is optionally substituted and one or more carbon atoms of the chain may be replaced by a heteroatom selected from oxygen, sulfur, and nitrogen. In one embodiment, the linker is comprised of an atom selected from hydrogen, oxygen, carbon, sulfur, and nitrogen. In one embodiment, the linker is comprised of a branched or unbranched C1- 15It consists of an alkylene chain, where optionally one or more carbons (e.g., 1, 2, or 3 carbons, preferably 1 or 2, especially 1) are replaced by a heteroatom selected from O, N, or S, especially O or N, where the chain is optionally substituted by one or more groups (e.g., 1-3, e.g., 2 groups) independently selected from oxo, halogen, aryl group, heteroaryl group, carbocyclyl group, or heterocyclyl group. As used herein, alkylene refers to straight or branched chain alkylene, including, but not limited to, methylene, ethylene, propylene, iso-propylene, butylene, and tert-butylene. In one embodiment, alkylene refers to straight chain alkylene.
[0036] As used herein, "alkylene chain" means a saturated chain of carbon atoms having two points of attachment to other groups. Thus, for example, ethylene refers to the moiety -CH2CH2-.
[0037] In one embodiment, the linker comprises a secondary amine. Exemplary procedures for covalently attaching a heparin moiety to a polymer via a secondary amine are described in EP0086186B1, which is incorporated herein by reference in its entirety.
[0038] In one embodiment, the linker comprises a secondary amide.Thus, further representative procedures for covalently binding heparin moieties to surfaces via amidation reactions involving N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) or 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) are detailed in WO2012 / 123384A1 (incorporated herein in its entirety by reference).The same procedures can be applied to fragments of heparin.
[0039] In one embodiment, the linker comprises 1,2,3-triazole. A representative procedure for covalently linking heparin moieties to polymers via 1,2,3-triazole bonds is described in WO2010 / 029189A2 (Carmeda AB, incorporated herein by reference in its entirety). The same procedure can be applied to heparin fragments. This document describes the azide or alkyne functionalization of polyimines; the preparation of alkyne and azide functionalized heparins (both native heparin and nitrous acid decomposed heparin); and the reaction for linking derivatized heparins to derivatized polymers via 1,2,3-triazole linkers.
[0040] In one embodiment, the linker comprises thioether.A representative procedure for covalently linking heparin moieties to polymers via thioether bonds is described in WO2011 / 110684A1 (Carmeda AB et al., incorporated herein by reference in its entirety).The same procedure can be applied to heparin fragments.
[0041] In one embodiment, the plurality of heparin fragments is not covalently attached to the surface via a thioether or 1,2,3-triazole.In one embodiment, the plurality of heparin fragments is not covalently attached to the surface via a thioether-containing linker or a 1,2,3-triazole-containing linker.
[0042] The linker can be attached to the reducing or non-reducing end of the heparin fragment, preferably to the reducing end. Preferably, the linker is attached to the heparin fragment at a single point, more preferably at a terminal point. More preferably, the linker is attached to the heparin fragment via the reducing end of the heparin fragment, more preferably, the linker is attached to the heparin fragment via position C1 of the reducing end of the heparin fragment. In such an embodiment, the linker can be preferably incorporated during the synthesis of the heparin fragment. In such an embodiment, the linker structure and the attachment point to the heparin fragment are compatible with the reaction conditions used in the synthesis.
[0043] In one embodiment, the linker has a molecular weight of 14 to 200, preferably 14 to 100 Da. 3 Å, more preferably 20 to 10 2 Å, more preferably 30-100 Å. In one embodiment, the linker consists of 3-50 atoms, preferably 6-36 atoms, preferably 9-30 atoms, preferably 12-22 atoms, preferably about 19 atoms.
[0044] In one embodiment, the fragment of heparin is covalently attached to the surface via a linker, and the linker has the formula (I): (I) (CH2) n NHCO(CH2) m (In the formula, n is 1 to 20, and m is 1 to 20.) Includes.
[0045] More preferably, n is 2 to 15, more preferably 3 to 9, more preferably 4 to 6, and more preferably 5. Preferably, m is 2 to 10, more preferably 3 to 5, and more preferably 4.
[0046] Table 1 below provides examples of linkers suitable for binding heparin fragments to surfaces, along with the functional groups from which the covalent linkers are formed and the type of reaction used.See, for example, reference (ISBN: 978-0-12-370501-3, Bioconjugate Techniques, 2nd Edition, 2008, fully incorporated herein by reference).However, radical coupling reactions can also be envisaged. [Table 1] Table 1: Exemplary Linkers
[0047] For each linker, one of the functional end groups is on the surface and the other on the heparin fragment. In principle, either format is possible, i.e., see Table 1, functional groups 1 and 2 can be on the surface and on the heparin fragment, respectively, or on the heparin fragment and on the surface, respectively.
[0048] Exemplary chemical reactions are discussed below:
[0049] (-C-NH-C-bond) Reductive amination: Also known as reductive alkylation, reductive amination is a form of amination that involves the conversion of a carbonyl group to an amine linker via an intermediate imine (Schiff base). The carbonyl group is most commonly a ketone or aldehyde. [ka]
[0050] (-C-NH-CHR-CHR-C(=O)-bond) Michael Addition: The Michael reaction or Michael addition is the nucleophilic addition of a carbanion or another nucleophile (e.g., a primary amine or a thiol) to an α,β-unsaturated carbonyl compound. It belongs to the larger class of conjugate additions. It is one of the most useful methods for the formation of mild C-C bonds.
[0051] (-CSC-bond) Thio-bromo:thioether bonds are usually prepared by alkylation of thiols, which can be reacted with bromide compounds to produce thioether bonds. Such reactions are usually carried out in the presence of a base, which converts the thiol to the more nucleophilic thiolate.
[0052] Thiol-ene and thiol-yne: Alternatively, thioether bonds can be prepared by reaction of a first compound containing a thiol group with a second compound containing an alkene or alkyne group. The first and second compounds can be a surface and a heparin fragment, respectively, as appropriate.
[0053] Suitably, the reaction takes place in the presence of a reducing agent such as tris(2-carboxyethyl)phosphine hydrochloride or, alternatively, dithiothreitol or sodium borohydride to avoid or reverse the effect of undesired coupling of two thiol groups by oxidation.
[0054] In one embodiment, the reaction is initiated using a radical initiator. An example of a radical initiator is 4,4'-azobis(4-cyanovaleric acid). Further examples are potassium persulfate, 2,2'-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride, azobisisobutyronitrile (AIBN), 1,2-bis(2-(4,5-dihydro-1H-imidazol-2-yl)propan-2-yl)diazene dihydrochloride, 2,2'-(diazene-1,2-diyl)bis(2-methyl-1-(pyrrolidin-1-yl)propan-1-imine)dihydrochloride, 3,3'-((diazene-1,2-diylbis(1-imino-2-methylpropane-2,1-diyl))bis(azanediyl))dipropanoic acid tetrahydrate, benzophenone, and derivatives of benzophenone, such as 4-(trimethylammoniummethyl)benzophenone chloride. A further example is ammonium persulfate.
[0055] In another embodiment, the reaction is not initiated using a radical initiator. Instead, higher pH conditions (e.g., pH 8-11) are used. This type of reaction is more suitable when an activated alkene or alkyne is used to react with a thiol.
[0056] The reaction between a first compound containing a thiol group and a second compound containing an alkyne group can be represented as follows: [ka] (In the formula, R a and R b One of them is the surface, and R a and R b The other of these is a heparin fragment.
[0057] When an alkene containing linker is formed, this compound can undergo further chemical transformation, for example with a thiol or amine. When the second compound is derivatized with an alkene, in one embodiment, an activated alkene is used. An example of a suitable activated alkene is a maleimide derivative.
[0058] The reaction between a first compound containing a thiol group and a second compound containing a maleimide group can be represented as follows: [ka] (In the formula, R a and R b One of them is the surface, and R a and R b (The other of these is a heparin fragment.) The reaction is usually carried out under acidic conditions in the presence of tris(2-carboxyethyl)phosphine hydrochloride as a reducing agent and 4,4'-azobis(4-cyanovaleric acid) as a radical initiator.
[0059] (Triazole bond (CuAAC coupling)) Azide-alkyne: 1,2,3-triazole bond can be prepared by reaction of alkyne with azide compound. The reaction to form linker can be between alkyne group on heparin fragment or surface and azide group on other of said heparin fragment or surface. The method to carry out this reaction is similar to the method described in WO 2010 / 029189 (incorporated herein in its entirety by reference).
[0060] The reaction between azide and alkyne groups can be carried out using reaction conditions conventionally used in Huisgen cycloadditions (1,3-dipolar cycloaddition of azides and terminal alkynes to form 1,2,3-triazoles) at elevated temperatures (T>60° C.) or in the presence of a metal catalyst, e.g., copper, e.g., a Cu(I) catalyst. The Cu(I) catalyst can be generated in situ, if desired, e.g., by reduction of the corresponding Cu(II) compound, e.g., with sodium ascorbate. The reaction can also be carried out under flow conditions, if desired.
[0061] The CuAAC reaction can be carried out, for example, at a temperature of about 5-80° C., preferably at about room temperature. The pH used in the reaction can be about 2-12, preferably about 4-9, and most preferably about 7. Suitable solvents include those in which the azide or alkyne bound entity is soluble, such as dimethylsulfoxide, dimethylformamide, tetrahydrofuran, and preferably water or a mixture of water and one of the above. The ratio of the entity to the surface can be adjusted to provide the desired density of entities on the surface.
[0062] (-C(=O)-N-bond) Amidation: Amides are commonly formed by the reaction of carboxylic acids with amines. Carboxylic acids and carboxylic acid derivatives can undergo many chemical transformations, usually through attack on the carbonyl, which breaks the carbonyl double bond and forms a tetrahedral intermediate. Thiols, alcohols, and amines are all known to act as nucleophiles. Amides are less reactive than esters under physiological conditions.
[0063] Amidation using activated acids: Activated acids (essentially esters with good leaving groups, e.g., NHS-activated acids) can react with amines to form amide linkers under conditions where normal carboxylic acids would simply form salts.
[0064] (-CSS-CH2-CH2-C(=O)-N-bond) Coupling with SPDP Reagents: N-Succinimidyl 3-(2-pyridyldithio)propionate (SPDP) and its analogs belong to a group of unique amine- and thiol-reactive heterobifunctional bond-forming reagents that give rise to disulfide-containing bonds.
[0065] Reductive amination, Michael addition, thio-bromo reaction, amidation with NHS-activated acid, coupling with SPDP reagents, CuAAC, and thiol-ene coupling are all suitable to provide safe coupling conditions and high yields of linker formation.
[0066] The groupings detailed above are for illustrative purposes only, and it will be appreciated that alternative or different functional groups may be utilized, for example, an amine group may be located on a secondary carbon, or the aliphatic chains depicted may be replaced by aromatic groups.
[0067] (Free radical initiated reaction) As briefly mentioned above, the functional end groups of the surface can be coupled to the heparin fragments by linkers formed by free radical initiated reactions. The radicals can be generated, for example, by heat, photolysis (e.g., Norrish type I and / or Norrish type II reactions), ionization, oxidation, plasma, or electrochemical reactions. For example, when a surface having free primary amine groups is treated with benzophenone, radicals such as carbon or oxygen radicals are generated that can participate in free radical initiated reactions (e.g., reactions with alkenes).
[0068] In one embodiment, the linker comprises a secondary amine bond. In particular, the linker may comprise an -NH- group; in another embodiment, the linker comprises an amide bond. In particular, the linker may comprise an -NH-C(O)- group; in another embodiment, the linker comprises a thioether bond. In another embodiment, the linker comprises a 1,2,3-triazole bond. The term "thioether bond" refers to a bond between a sulfur and two carbon atoms. This bond is sometimes called a "sulfide". The sulfur may be bonded to two saturated carbon atoms (i.e., -CSC-), or it may be bonded to a saturated and an unsaturated carbon atom (i.e., -CSC=-). The term "thiol" refers to a -SH moiety. The term "secondary amine bond" refers to a bond between an NH group and two carbon atoms, i.e., -C-NH-C-. The term "amide bond" refers to a bond between two carbon atoms of the type -CC(O)NH-C-.
[0069] In one embodiment, the linker between the heparin fragment and the surface functional end group is a non-branched linker. The linker can be biodegradable or non-biodegradable, but more preferably is non-biodegradable so that the coated device is non-thrombogenic for extended periods of time.
[0070] When multiple linkers are present, some or all of them can be of different types, hi one embodiment, the linkers are all of the same type.
[0071] The heparin fragment can be attached to the surface directly (i.e., without a linker). Thus, in one embodiment, the heparin fragment is not covalently attached to the surface via any linker.
[0072] Covalent attachment to the surface must not destroy the active pentasaccharide sequence. Preferably, the covalent attachment does not interfere with the active pentasaccharide sequence. In the case of a heparin fragment consisting of five sugar units, since all sugar units in the pentasaccharide are essential for AT binding, immobilization must be achieved in such a way that the active sequence is not destroyed. Indeed, it is therefore preferred to use a linker in conjunction with the pentasaccharide fragment at either the reducing or non-reducing end point so that the immobilization does not destroy the active sequence. Thus, in one embodiment, when a plurality of heparin fragments contain any pentasaccharide, these pentasaccharides are covalently attached to the surface via a linker. Preferably, the pentasaccharide is a synthetically produced pentasaccharide, and the linker is incorporated into the structure during its synthesis. Preferably, the linker is incorporated into the terminal sugar, preferably the reducing end sugar and, for example, at the C1 position.
[0073] Various fragments of heparin can be immobilized on a surface directly or via a linker, including those discussed herein. However, in some circumstances, this may not be practical if the preferred attachment point on the heparin fragment is blocked. An example of this is the pentasaccharide fondaparinux (a synthetically prepared heparin fragment, FIG. 4), which contains the active sequence of heparin. In native heparin, the only position in the structure where synthetic end-point modification is possible is the anomeric carbon in the reducing end. In fondaparinux, this anomeric center is modified with a methyl group, protecting the reactive aldehyde group at the reducing end and effectively blocking further modification. Therefore, fondaparinux is not a suitable heparin fragment for immobilization.
[0074] The advantage of immobilizing synthetically derived heparin fragments is that any heparin fragment can potentially contain an active site that mediates interaction with AT. It is attractive to immobilize synthetically derived heparin fragments containing the active sequence A on a surface, since the inventors have shown that immobilization can overcome the disadvantage of shorter heparin fragments (i.e., their inability to inhibit FIIa when in solution).
[0075] The example below involves the synthesis of a pentasaccharide containing the active sequence of heparin substituted with a linker. Similar to fondaparinux, this synthetic pentasaccharide retained the ability to inhibit FXa in solution. Figure 5 shows a retrosynthetic scheme including building blocks (A-E) that were coupled to form the pentasaccharide with a linker. The linker was successfully incorporated at the reducing end, allowing end-point attachment to surfaces without destroying the active sequence A.
[0076] In one embodiment, a method of making an anticoagulant surface is provided, comprising covalently attaching to a surface a plurality of fragments of heparin, wherein the fragments consist of 5 to 18 saccharide units, and at least a portion of the plurality of fragments has the polysaccharide sequence A: [ka] (Wherein, R=Ac or SO3 - is) Including, This surface catalyzes the inhibition of FIIa and FXa, Here, the heparin fragments are covalently attached to the surface via a linker.
[0077] In one embodiment, the heparin fragment and the linker attached thereto are simultaneously synthesized, and then the heparin fragment with the linker is covalently attached to a surface. In one embodiment, an anticoagulant surface obtained by this method is provided. In one embodiment, an anticoagulant surface obtained by this method is provided.
[0078] (Spacer) The covalent bond between the functional end group of the surface and the heparin fragment may be direct or via a linker as discussed above. Optionally, however, the linker may be separated from the surface by a spacer. Thus, all of the above embodiments relating to a linker attached to a surface in the "Linker" section are equally applicable to a linker attached to a spacer and / or a spacer attached to a surface.
[0079] When utilized, the purpose of the spacer is usually to significantly increase the distance between the surface and the heparin fragment. For example, the molecular weight of the spacer is between 50 and 10 6 Da, typically 100 to 10 6 Da, e.g., 100 to 10 4 The length of the spacer can be, for example, 10 to 10 3 Preferably the spacer is linear.
[0080] In one embodiment, the spacer is comprised of an alkylene chain, which is optionally substituted and one or more carbon atoms of the chain may be replaced by a heteroatom selected from oxygen, sulfur, and nitrogen. In one embodiment, the spacer is comprised of atoms selected from hydrogen, oxygen, carbon, sulfur, and nitrogen. In one embodiment, the spacer is comprised of a branched or unbranched C1- 15It consists of an alkylene chain, where optionally, one or more carbons (e.g., 1, 2, or 3 carbons, preferably 1 or 2, especially 1) are replaced by a heteroatom selected from O, N, or S, especially O or N, where the chain is optionally substituted by one or more groups (e.g., 1-3, e.g., 2 groups) independently selected from oxo, halogen, aryl group, heteroaryl group, carbocyclyl group, or heterocyclyl group. As used herein, alkylene refers to straight or branched chain alkylene, such as, but not limited to, methylene, ethylene, propylene, iso-propylene, butylene, and tert-butylene. In one embodiment, alkylene refers to straight chain alkylene.
[0081] The spacer suitably contains a functional group that can be attached to a heparin fragment (or linker) at one end and covalently attached to a surface at the other end.
[0082] In one embodiment, the spacer consists of a linear alkyl chain substituted at either end with a functional group that is connected to a heparin fragment (or linker) at one end and capable of covalently binding to a surface at the other end.
[0083] In some embodiments, the spacer is hydrophilic, for example, it may comprise a PEG chain. In one embodiment, the covalent connection between the functional end group of the surface and the heparin fragment may be considered to have three moieties - a "spacer A" between the functional end group of the surface and the linker, the linker, and a "spacer B" between the linker and the heparin fragment. In one embodiment, the molecular weight of spacer A is 50 to 10 3 In another embodiment, the molecular weight of spacer B is 50 to 10 Da. 3Da. In one embodiment, spacer A comprises one or more aromatic rings. In another embodiment, spacer A does not comprise an aromatic ring. In one embodiment, spacer B comprises one or more aromatic rings. In another embodiment, spacer B does not comprise an aromatic ring. In one embodiment, spacer A is hydrophilic. In another embodiment, spacer B is hydrophilic. In one embodiment, spacer A comprises a PEG chain. In another embodiment, spacer B comprises a PEG chain. In one embodiment, both spacers A and B are hydrophilic, e.g., they each comprise a PEG chain. As used herein, a PEG chain is typically between 100 and 10 6 It refers to a polymer chain obtainable by polymerization of ethylene oxide of weight Da. In another embodiment, the covalent bond may include one or more triazole rings.
[0084] If a spacer is present, it is about 10-10 3 In one embodiment, the spacer has a molecular weight of 14-200, preferably 14-100 Da. In one embodiment, the spacer consists of 3-50 atoms, preferably 6-36 atoms, preferably 9-30 atoms, preferably 12-22 atoms, preferably about 19 atoms.
[0085] A particular advantage of having a spacer that includes PEG chains (or other hydrophilic polymers) is that it provides a lubricious nature to the surface.
[0086] The spacer can be biodegradable or non-biodegradable, but more preferably is non-biodegradable so that the coated device is non-thrombogenic (i.e., the coated device has sustained non-thrombogenicity) for extended periods of time.
[0087] The linker-substituted pentasaccharide can be reacted with an aldehyde-substituted spacer that allows immobilization to the outermost layer of a polyamine via reductive amination, essentially as described by Larm et al. in EP0086186A1 and EP0495820B1, which are incorporated by reference in their entirety. See Figure 6.
[0088] The spacer may be attached to the linker and / or the surface by various means. In one embodiment, the spacer comprises a secondary amine. A representative procedure for covalently attaching a heparin moiety to a polymer via a secondary amine is described in EP0086186B1, which is incorporated herein by reference in its entirety. In one embodiment, the spacer comprises a secondary amide. In one embodiment, the spacer comprises a 1,2,3-triazole. In one embodiment, the spacer comprises a thioether. In one embodiment, the multiple heparin fragments are not covalently attached to the surface via a thioether-containing spacer or a 1,2,3-triazole-containing spacer.
[0089] The spacer can be attached to the reducing or non-reducing end of the heparin fragment, preferably to the reducing end. Preferably, the spacer is attached to the heparin fragment at a single point, more preferably at a terminal point. More preferably, the spacer is attached to the heparin fragment via the reducing end of the heparin fragment, and more preferably, the spacer is attached to the heparin fragment via position C1 of the reducing end of the heparin fragment.
[0090] The exemplary linkers provided in Table 1 above also represent examples of spacers suitable for attaching the spacer to the linker and / or surface. For each spacer in this table, one of the functional end groups is on the surface and / or linker, and the other is on the spacer. The exemplary chemical reactions provided in Table 1 below can also be applied in attaching the spacer to the linker and / or surface.
[0091] (anticoagulant properties) As discussed above, the present inventors have surprisingly discovered that a preparation of heparin-derived oligosaccharides (i.e., heparin fragments) capable of catalyzing the inhibition of FXa by AT but lacking the ability to catalyze the inhibition of FIIa by AT in solution can catalyze both reactions when immobilized on a surface. Thus, when such a preparation is immobilized on a surface according to the present invention, the surface acquires anticoagulant properties.
[0092] Without wishing to be bound by theory, it is believed that the immobilized oligosaccharides are organized in a manner that may allow them to act synergistically and / or by forming "bridges" between the oligosaccharides, allowing binding and AT-mediated FIIa inhibition. Such activity would seemingly require a fairly long molecule in solution. This concept is illustrated in the examples below for various heparin fragments. In particular, an octasaccharide fragment of heparin has been prepared and covalently attached to a surface. Furthermore, a pentasaccharide has been synthesized that contains the active sequence of heparin substituted with a linker (like fondaparinux, which has the ability to inhibit FXa in solution but not FIIa in solution). It has been shown that heparin fragments, when covalently attached to a surface according to the invention, are surprisingly capable of inhibiting both FXa and FIIa.
[0093] It is important to note that the surfaces of the invention comprising heparin fragments are not only anticoagulant because they inhibit FXa, but their anticoagulant properties are enhanced by their ability to also inhibit FIIa. The anticoagulant properties of a surface can be assessed by a variety of means. The anticoagulant properties of exemplary surfaces of the invention are demonstrated using the assessment methods provided in the Examples.
[0094] In one embodiment, a surface according to the present invention is provided, wherein the surface inhibits FIIa activity by at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, more preferably at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, or more preferably at least 95%, when measured according to evaluation method G.
[0095] Suitably, the surface of the invention is for use in catalysing the inhibition of FIIa by AT.
[0096] In one embodiment, there is provided the use of an anticoagulant surface, the surface having a plurality of heparin fragments covalently attached thereto, wherein the fragments consist of 5 to 18 saccharide units, and at least a portion of the plurality of fragments comprises the polysaccharide sequence A for catalyzing the inhibition of FIIa by AT. (Wherein, R=Ac or SO3 - is) Includes.
[0097] In one embodiment, an anticoagulant surface is provided, the surface having a plurality of heparin fragments covalently attached thereto, wherein the fragments consist of 5 to 18 saccharide units, and at least a portion of the plurality of fragments comprises polysaccharide sequence A for use in catalyzing the inhibition of FIIa by AT. (Wherein, R=Ac or SO3 - is) Includes.
[0098] In one embodiment, a composition is provided comprising a plurality of fragments of heparin for use in increasing FIIa inhibitory activity of a surface, wherein the plurality of fragments of heparin are covalently attached to the surface, and the fragments consist of 5 to 18 saccharide units, and at least a portion of the plurality of fragments comprises the polysaccharide sequence A. (Wherein, R=Ac or SO3 - is) Includes.
[0099] In one embodiment, there is provided a use of a composition comprising a plurality of heparin fragments for increasing FIIa inhibitory activity of a surface, wherein the plurality of heparin fragments are covalently attached to the surface, and the fragments consist of 5 to 18 saccharide units, and at least a portion of the plurality of fragments comprises the polysaccharide sequence A. (Wherein, R=Ac or SO3 - is) Includes.
[0100] In one embodiment, a surface according to the invention is provided, wherein the surface inhibits FXa activity by at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, more preferably at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, or more preferably at least 95%, when measured according to Evaluation Method F.
[0101] Preferably, the heparin fragment to be bound to a surface according to the invention has FXa inhibitory activity before it is bound to the surface (i.e., when it is in solution). Thus, preferably, the heparin fragment has an FXa inhibitory activity of at least 1 IU / mg, more preferably 5 IU / mg, more preferably 10 IU / mg, more preferably 15 IU / mg, more preferably >100 IU / mg prior to immobilization, as measured according to Evaluation Method C.
[0102] Fragments of heparin immobilized according to the invention have the capacity to bind AT (expressed as pmol AT / surface unit), which capacity is sometimes referred to as "heparin activity". Thus, surfaces according to the invention have an activity of at least 0.1 pmol / surface cm for binding AT, as measured according to Evaluation Method J. 2 , preferably at least 1 pmol / cm of surface 2 , preferably at least 2 pmol / cm of surface 2 It may have heparin activity of 100%.
[0103] (surface) Any surface can have multiple heparin fragments covalently attached to it according to the invention. Preferably, the surface contains functional groups such as amines, thiols, or hydroxyl groups that can be reacted with the reducing ends of the heparin fragments (or linkers or spacers attached thereto).
[0104] In some embodiments, the surface can be coated and fragments of heparin can be covalently attached to the coating. The coating can suitably comprise anionic and / or cationic polymers and / or non-charged polymers, such as, for example, polydopamine or fluorine-containing polymers.
[0105] In certain embodiments of the invention, the surface (also referred to herein as "anticoagulant surface") can exhibit direct pharmacological inhibition of the coagulation response by immobilization of anticoagulant entities (fragments of heparin). In certain embodiments of the invention, the anticoagulant surface does not induce significant clinically significant adverse reactions, such as thrombosis, hemolysis, platelet, leukocyte, and complement activation, and / or other blood-related adverse events, when in contact with blood.
[0106] (solid object) In one embodiment, a solid object is provided that comprises a surface according to the present invention.While any solid object can potentially be coated with a surface according to the present invention (also referred to herein as "anticoagulant surface"), such coating is particularly useful for medical devices, analytical devices, separation devices, and other industrial products, including membranes.Most preferably, the solid object is a medical device.Surface can also refer to a coating on a solid object or the surface of the solid object itself.
[0107] In one embodiment, the solid object is a medical device. When the solid object is a medical device, it is preferably an anticoagulant medical device. Thus, in one embodiment, the solid object is an anticoagulant medical device. As used herein, the term "medical device" refers to an internal or external device, but more preferably refers to an internal medical device.
[0108] An internal medical device is a device that is used within a biological structure, for example, within the vasculature or other body lumen, space, or cavity, usually to provide a therapeutic effect. An internal device can be for long-term or temporary use. A device for long-term use, such as a stent or stent-graft, is placed in the biological structure in part or in whole after a direct surgical procedure to deliver it. Devices for temporary or short-term use include those that are inserted temporarily (i.e., inserted and then removed in the same surgical procedure) in the treatment area, such as a medical balloon. In one embodiment, the solid object is an internal medical device.
[0109] Examples of intracorporeal medical devices, which can be permanent or temporary intracorporeal medical devices, include stents, including bifurcated stents, balloon expandable stents, self-expanding stents, neurovascular stents, and shunt stents; stent-grafts, including bifurcated stent-grafts; grafts, including vascular grafts and bifurcated grafts; retractable sheaths, e.g., interventional diagnostic and therapeutic sheaths, large and standard bore intravascular delivery sheaths, sheaths, including arterial introducer sheaths with and without hemostatic control and with and without steering, microintroducer sheaths, dialysis access sheaths, guiding sheaths, and percutaneous sheaths; dilators. , occlusion devices, e.g., vascular occlusion devices, embolic filters, embolus removal devices, catheters, artificial blood vessels, blood intrinsic monitoring devices, valves, including artificial heart valves, pacemaker electrodes, guidewires, cardiac leads, cardiopulmonary bypass circuits, cannulas, plugs, drug delivery devices, balloons, tissue patch devices, blood pumps, patches, lines, e.g., chronic infusion lines or arterial lines, indwelling wires, devices for continuous subarachnoid infusion, feeding tubes, CNS shunts, e.g., ventriculopleural shunts, ventriculoatrial (VA) shunts, ventriculoperitoneal (VP) shunts, ventriculoatrial shunts, portosystemic shunts, and shunts for ascites.
[0110] Examples of catheters include, but are not limited to, microcatheters, central venous catheters, peripheral intravenous catheters, hemodialysis catheters, catheters such as implantable venous catheters, tunneled venous catheters, coated catheters including coronary artery catheters useful for angiography, angioplasty, or ultrasound procedures in the heart or in peripheral veins and arteries, catheters containing spectroscopy or imaging capabilities, hepatic artery infusion catheters, CVCs (central venous catheters), peripheral intravenous catheters, peripherally inserted central catheters (PIC lines), flow direct balloon tipped pulmonary artery catheters, total parenteral nutrition catheters, long term catheters (e.g., long term gastrointestinal catheters and long term genitourinary catheters), peritoneal dialysis catheters, CPB catheters (cardiopulmonary bypass), urinary catheters, and microcatheters (e.g., for intracranial applications).
[0111] In one embodiment, the solid object is an intracorporeal medical device selected from the group consisting of a stent, a stent-graft, a sheath, a dilator, an occluder, a valve, an embolic filter, an embolus removal device, a catheter, a vascular graft, a blood intrinsic monitoring device, a valve, a pacemaker electrode, a guidewire, a cardiac lead, a cardiopulmonary bypass circuit, a cannula, a plug, a drug delivery device, a balloon, a tissue patch device, a blood pump, a patch, a line, an indwelling wire, a device for continuous intrathecal infusion, a feeding tube, and a shunt. In a specific embodiment, the solid object is a stent or a stent-graft.
[0112] In one embodiment, the intracorporeal medical device can be used in neurological, peripheral, cardiac, orthopedic, dermatological, or gynecological applications. In one embodiment, the stent can be used in cardiac, peripheral, or neurological applications. In one embodiment, the stent-graft can be used in cardiac, peripheral, or neurological applications. In one embodiment, the sheath can be used in carotid, renal, transradial, transseptal, pediatric, or micro applications.
[0113] Examples of extracorporeal medical devices are blood treatment devices and blood transfusion devices. In one embodiment, the intracorporeal medical device can be used in neurological, peripheral, cardiac, orthopedic, dermatological, or gynecological applications. In one embodiment, the extracorporeal medical device is an oxygenator. In another embodiment, the extracorporeal medical device is a filter that can remove viruses, bacteria, pro-inflammatory cytokines that cause sepsis, and toxins.
[0114] The membrane can be, for example, a hemodialysis membrane.
[0115] An analytical device can be, for example, a solid support for carrying out an analytical process such as chromatography or an immunological assay, reactive chemistry, or catalysis. Examples of such devices include slides, beads, well plates, and membranes.
[0116] A separation device can be, for example, a solid support for carrying out a separation process such as protein purification, affinity chromatography, or ion exchange. Examples of such devices include filters and columns.
[0117] The solid object can include or be formed of, inter alia, metals, synthetic or natural organic or inorganic polymers, ceramic materials, protein-based materials, or polysaccharide-based materials.
[0118] Suitable metals include, but are not limited to, biocompatible metals such as titanium, stainless steel, high nitrogen stainless steel, cobalt, chromium, nickel, tantalum, niobium, gold, silver, rhodium, zinc, platinum, rubidium, copper and magnesium, and combinations (alloys) thereof.Suitable alloys include cobalt-chromium alloys, such as L-605, MP35N, Elgiloy, titanium alloys including nickel-titanium alloys (e.g., Nitinol), tantalum alloys, niobium alloys (e.g., Nb-1%Zr), and others.In one embodiment, the biocompatible metal is nickel-titanium alloy, such as Nitinol.
[0119] Synthetic or natural organic or inorganic polymers include polyolefins, polyesters (e.g., polyethylene terephthalate and polybutylene terephthalate), polyester ethers, polyester elastomeric copolymers (e.g., those available under the trade name HYTREL® from Wilmington, such as those available from DuPont, Del.), fluorine-containing polymers, chlorine-containing polymers (e.g., polyvinyl chloride (PVC)), block copolymer elastomers (e.g., copolymers having styrene end blocks and midblocks formed from butadiene, isoprene, ethylene / butylene, ethylene / propene), block copolymers (e.g., styrenic block copolymers, such as acrylonitrile-styrene and acrylonitrile-butadiene-styrene block copolymers, or block copolymers (certain block copolymer thermoplastic elastomers where the block copolymer is composed of polyester or polyamide hard segments and polyether soft segments), polyurethanes, polyamides (e.g., nylon 12, nylon 11, nylon 9, nylon 6 / 9, and nylon 6 / 6), polyether block amides (e.g., PEBAX®), polyether esters, Examples of suitable materials include steramides, polyimides, polycarbonates, polyphenylene sulfides, polyphenylene oxides, polyethers, silicones, polycarbonates, polyhydroxyethyl methacrylates, polyvinylpyrrolidones, polyvinyl alcohols, rubbers, silicone rubbers, polyhydroxy acids, polyallylamines, polyallyl alcohols, polyacrylamides, polyacrylic acids, polystyrenes, polytetrafluoroethylenes, poly(methyl)methacrylates, polyacrylonitriles, poly(vinyl acetates), poly(vinyl alcohols), polyoxymethylenes, polycarbonates, phenols, amino-epoxy resins, cellulosic plastics, and rubber-like plastics, bioabsorbable (e.g., poly(D,L-lactides) and polyglycolides, and copolymers thereof, derivatives thereof, and mixtures thereof. Combinations of these materials, with and without crosslinking, can be utilized.Some of these classes are available as both thermosets and thermoplastic polymers. As used herein, the term "copolymer" shall be used to refer to any polymer formed from two or more monomers, e.g., 2, 3, 4, 5, etc.
[0120] Fluorinated polymers (fluorine-containing polymers) include fluoropolymers such as expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), fluorinated ethylene-propylene (FEP), perfluorocarbon copolymers (e.g., tetrafluoroethylene perfluoroalkyl vinyl ether (TFE / PAVE) copolymers and copolymers of tetrafluoroethylene (TFE) and perfluoromethyl vinyl ether (PMVE)), and combinations of the above with and without crosslinking between polymer chains.
[0121] In one embodiment, the solid object comprises a polyether-block-amide, such as PEBAX®. In another embodiment, the solid object comprises a chlorine-containing polymer (e.g., PVC) or a fluorine-containing polymer (e.g., ePTFE).
[0122] The polymeric substrate can optionally be blended with fillers and / or colorants. Thus, suitable substrates include colored materials, such as colored polymeric materials.
[0123] Ceramic substrates can include, but are not limited to, silicone oxide, aluminum oxide, alumina, silica, hydroxyapapitite, glass, calcium oxide, polysilanols, and phosphorus oxide.
[0124] Protein-based materials include silk and wool.Polysaccharide-based materials include agarose and alginates.
[0125] (cationic and anionic polymers) Preferably, the surface comprises one or more layers of cationic and / or anionic polymer. Preferably, the heparin fragment is attached to the outermost layer of the cationic polymer, preferably via a linker. In one embodiment, a solid object is provided, the surface of which comprises a layer-by-layer coating, the outer coating layer being a cationic polymer to which the heparin fragment is covalently attached. Preferably, the layer-by-layer coating is an alternating layer of cationic polymer and anionic polymer. More preferably, the cationic polymer layer is a layer of cationic polymeric amine, and / or the anionic polymer layer is a layer of dextran sulfate.
[0126] The cationic polymer may be a linear polymer, but is more commonly a branched polymer, such as a hyperbranched polymer. In one embodiment, the branched polymer has a consistent branched structure with a distinct feature, such as a core portion. In another embodiment, the branched polymer has a consistent or randomly branched structure that lacks a distinct feature, such as a core portion. A "core portion" is a group that may be present (typically at the center) in the branched polymer molecule from which the dendritic branching structure of the branched polymer emanates.
[0127] In one embodiment, the cationic polymer is a branched cationic polymer. The cationic polymer is optionally crosslinked. In one embodiment, the cationic polymer comprises primary / secondary amine groups. In one embodiment, the cationic polymer is preferably a polyamine optionally crosslinked with a difunctional aldehyde. The cationic polymer (e.g., polyamine) preferably has a molecular weight of 5 kDa to 3,000 kDa, for example, 5 kDa to 2,000 kDa, 5 kDa to 1,500 kDa, 5 kDa to 1,000 kDa, 5 kDa to 800 kDa, 5 kDa to 500 kDa, 5 kDa to 300 kDa, 5 kDa to 200 kDa, or 800 kDa to 3,000 kDa. The cationic polymer (e.g., polyamine) preferably has a molecular weight of at least 5 kDa, such as at least 10 kDa, such as at least 25 kDa, such as at least 50, such as at least 60, such as at least 70 kDa. The cationic polymer (e.g., polyamine) preferably has a molecular weight of 2000 kDa or less, such as 1500 kDa or less, such as 1300 kDa or less, such as 1200 kDa or less, such as 1100 kDa or less, such as 1000 kDa or less. When the cationic polymer (e.g., polyamine) is crosslinked, it is preferably crosslinked using an aldehyde crosslinker such as crotonaldehyde and / or glutaraldehyde. In one embodiment, the cationic polymer is a polyalkyleneimine, such as a polyethyleneimine.
[0128] Preferably, the heparin fragments are covalently attached to the outermost layer of the cationic polymer.
[0129] The cationic polymer can form part of a layer-by-layer coating of cationic and anionic polymers formed by treating the surface of the solid object with alternating layers of cationic and anionic polymers. A bilayer is defined herein as one layer of cationic and anionic polymers. In a layer-by-layer coating, the cationic polymer is usually applied before the anionic polymer, i.e., the surface of the solid object is usually first treated with a first layer of cationic polymer (step i), and a first layer of anionic polymer is applied on top of the first layer (step ii). Depending on the number of bilayers required, further layers of cationic and anionic polymers can be applied (step iii). Once the last (which can also be the first) bilayer of cationic and anionic polymers is completed, a layer of cationic polymer is then applied (step iv). This layer of cationic polymer (i.e., the outermost layer) is then treated with heparin fragments to covalently bond the heparin fragments to the layer of cationic polymer. Thus, the outer coating layer of cationic polymer can be said to "comprise" heparin fragments. In the layer-by-layer coating, the innermost layer is a layer of cationic polymer and the outermost layer is an outer coating layer of cationic polymer to which fragments of heparin are covalently attached.
[0130] In one embodiment, the cationic polymer of step i is an optionally crosslinked polyamine. In one embodiment, the cationic polymer of step iv is an optionally crosslinked polyamine. In one embodiment, the cationic polymer of step i is the same as the cationic polymer of step iv.
[0131] WO2012 / 123384A1 (Gore Enterprise Holdings et al., incorporated herein by reference in its entirety) discloses a device having a coating comprising a plurality of hyperbranched polymer molecules bearing anticoagulant entities, in particular heparin. Such hyperbranched polymer molecules can be utilized in the outermost layer of cationic polymer, i.e., such hyperbranched polymers can be used as cationic polymers in step iv and then modified to bear heparin fragments in step v.
[0132] The anionic polymers suitable for the present invention possess deprotonated functional groups from the group consisting of -COOH, -SO3H, and -PO3H2. Thus, in one embodiment, the anionic polymer possesses a deprotonated functional group from the group consisting of -CO2 - , -SO3 - , -POH - , and -PO3 2- The polymer comprises a group selected from
[0133] The anionic polymer is preferably an anionic glycosaminoglycan or polysaccharide. The anionic character of the polymer usually comes from carboxylic acid or sulfate groups along the polymer chain. Thus, in one embodiment, the anionic polymer is a glycosaminoglycan or polysaccharide having carboxylic acid and / or sulfate groups, in particular a glycosaminoglycan having carboxylic acid and / or sulfate groups. The anionic polymer may be branched or unbranched. In one embodiment, the anionic polymer is optionally crosslinked.
[0134] In one embodiment, the anionic polymer is selected from the group consisting of dextran sulfate, hyaluronic acid, poly(2-acrylamido-2-methyl-1-propanesulfonic acid), poly(2-acrylamido-2-methyl-1-propanesulfonic acid-co-acrylonitrile)acrylonitrile, poly(acrylic acid), polyanetholsulfonic acid, poly(sodium 4-styrenesulfonate), poly(4-styrenesulfonic acid-co-maleic acid), poly(vinyl sulfate), polyvinylsulfonic acid, and salts thereof. Preferably, the anionic polymer is dextran sulfate. Dextran sulfate is a sulfated polymer of anhydroglucose. The degree of sulfation and, as a result, the sulfur content of dextran sulfate can vary.
[0135] In one embodiment, the anionic polymer is characterized by having a total molecular weight of 550 kDa to 10,000 kDa, for example, 650 kDa to 10,000 kDa, for example, 750 kDa to 10,000 kDa, for example, 1,000 kDa to 10,000 kDa. In one embodiment, the anionic polymer is characterized by having a total molecular weight of 650 kDa to 1,000 kDa, for example, 750 kDa to 1,000 kDa. In one embodiment, the anionic polymer is characterized by having a total molecular weight of 1,000 kDa to 4,500 kDa, for example, 2,000 kDa to 4,500 kDa. In one embodiment, the anionic polymer is characterized by having a total molecular weight of 4,500 kDa to 7,000 kDa. In one embodiment, the anionic polymer is characterized by having a total molecular weight of 7,000 kDa to 10,000 kDa. In one embodiment, the anionic polymer is characterized by having a total molecular weight of more than 1,000 kDa, for example, more than 2,000 kDa, for example, more than 3,000 kDa, for example, more than 3,500 kDa.Preferably, the anionic polymer is characterized by having a total molecular weight of less than 7,000 kDa, for example, less than 6,000 kDa, for example, less than 5,000 kDa, for example, less than 4,500 kDa.Preferably, the total molecular weight of the anionic polymer is measured according to evaluation method K.
[0136] In one embodiment, the anionic polymer is characterized by having a solution charge density of 1 μeq / g to 7 μeq / g, such as 2 μeq / g to 4 μeq / g, or alternatively, >4 μeq / g to 7 μeq / g, such as >5 μeq / g to 7 μeq / g. Suitably, the solution charge density of the anionic polymer is measured according to Evaluation Method L.
[0137] In some embodiments, the sulfur content in the cationic and / or anionic polymer is from 10% to 25% by weight, for example, the sulfur content is from 15% to 20% by weight.
[0138] The layer-by-layer coating can include one or more coating bilayers, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more coating bilayers.
[0139] Typically, the coating layer has an average total thickness of about 10 nm to about 1000 nm, e.g., about 10 nm to about 800 nm, e.g., about 10 nm to about 500 nm, about 10 nm to about 400 nm, about 10 nm to about 300 nm, about 10 nm to about 200 nm, or about 10 nm to about 100 nm. The coating thickness can be measured using a suitable coating thickness analyzer or gauge, by using X-ray photoelectron spectroscopy with depth profiling or by using a quartz crystal microbalance with dissipation.
[0140] In one embodiment, the surface does not include a laminate coating.
[0141] In one embodiment, the surface does not include a laminate coating in which the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by a core portion having a molecular weight of 14 to 1,000 Da and a ratio of total molecular weight to core portion molecular weight of at least 80:1.
[0142] In one embodiment, the surface does not include a layered coating comprising a plurality of cationic hyperbranched polymer molecules, the outer coating layer being characterized by having (i) a core portion having a molecular weight of 14 to 1,000 Da, (ii) a total molecular weight of 1,500 to 1,000,000 Da, (iii) a ratio of total molecular weight to core portion molecular weight of at least 80:1 (e.g., at least 100:1), and (iv) functional end groups, one or more of the functional end groups having an anticoagulant entity covalently attached thereto.
[0143] (Treatment method) The surfaces according to the invention are useful in medical therapy. In one aspect of the invention, a solid object (particularly a medical device such as a stent, graft, or stent-graft) according to the invention is provided for use in treating tissues in the human or animal body. The tissues to be treated include any body cavity, space, or hollow organ passage, such as blood vessels, urinary tract, intestinal tract, nasal cavity, nerve sheath, intervertebral area, bone cavity, esophagus, intrauterine space, pancreatic and bile ducts, rectum, and body spaces that have previously undergone intervention with implanted vascular grafts, stents, prostheses, or other types of medical implants. In yet another aspect of the invention, a solid object (particularly a medical device such as a stent, graft, or stent-graft) according to the invention can be positioned to treat aneurysms in the brain.
[0144] Solid objects according to the invention (particularly medical devices such as stents, grafts, or stent-grafts) may be useful for removing obstructions such as emboli and thrombi from blood vessels, as expansion devices to restore patency to occluded body passageways, as occlusion devices to selectively deliver means to block or fill passageways or spaces, and as centering mechanisms for transluminal instruments such as catheters.
[0145] In one embodiment, a solid object (particularly a medical device such as a stent, graft, or stent-graft) according to the present invention is provided for use in the prevention or treatment of stenosis or restenosis of a blood vessel in a human body. In another embodiment, a solid object (particularly a medical device such as a stent, graft, or stent-graft) according to the present invention is provided for use in the prevention or treatment of stenosis or restenosis of a blood vessel in a human body where a previously placed elution construct has failed. In another embodiment, a solid object (particularly a medical device such as a stent, graft, or stent-graft) according to the present invention can be used to establish or maintain an arteriovenous access site, for example a site used during renal dialysis. In a further embodiment, a solid object (particularly a medical device such as a stent, graft, or stent-graft, for example a vascular graft) according to the present invention can be used to redirect blood flow around an area of obstruction or vascular stenosis. In another embodiment, a solid object (particularly a medical device such as a stent, graft, or stent-graft) according to the present invention can be placed to restore patency to an area of a diseased blood vessel or to eliminate an aneurysm. In yet another embodiment, solid objects (particularly medical devices such as stents, grafts, or stent-grafts) according to the present invention can be placed to reinforce diseased blood vessels after angioplasty. In yet another embodiment, solid objects (particularly medical devices such as stents, grafts, or stent-grafts) according to the present invention can be placed in the brain using balloon-assisted or coil-assisted procedures.
[0146] In one embodiment, the solid objects (particularly medical devices) according to the present invention can be used for percutaneous transluminal angioplasty (PTA) in patients with peripheral arterial occlusive disease.
[0147] In another aspect of the present invention, there is provided a method for the prevention or treatment of stenosis or restenosis, comprising implanting a solid object (in particular a medical device) according to the present invention into a blood vessel in the human or animal body.
[0148] (abbreviation) Ac Acetyl ACN Acetonitrile Ac2O Acetic anhydride AcOH Acetic acid AgOTf Silver triflate AT, ATIII Antithrombin III BAIB Bis(acetoxy)iodobenzene BDMA Benzaldehyde dimethyl acetal Bn Benzyl Bu Butyl Bz Benzoyl Cbz Carboxybenzyl CNS Central Nervous System COSY correlation spectroscopy CPB cardiopulmonary bypass Cq quaternary carbon CSA (+ / -)-10-Camphorsulfonic Acid CVC Central Venous Catheter Dalton DBU 1,8-diazabicyclo(5.4.0)undec-7-ene DMF Dimethylformamide DMAPA Dimethylaminopropylamine EDC 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide EDA Ethylenediamine Et Ethyl Et2O Diethyl ether EtOAc Ethyl acetate EtOH Ethanol Eq equivalent FEP Fluorinated Ethylene Propylene FIIa Coagulation factor IIa, thrombin FXa Clotting factor Xa GPC Gel Permeation Chromatography HMBC heteronuclear multi-bond correlation spectroscopy HSQC Heteronuclear Single Quantum Coherence Spectroscopy HRMS High Resolution Mass Spectrometry HSA Human serum albumin HSEt Ethanethiol HSPh Thiophenol M Molar concentration MBTH 3-Methyl-2-benzothiazolinone hydrazone hydrochloride Me Methyl Ms. Meshir NIS N-iodosuccinimide NMR nuclear magnetic resonance OTCA Trichloroacetimidate OTf Triflate, Trifluoromethanesulfonate PAVE Perfluoroalkyl vinyl ether PES-Na Polyethylene Sodium Sulfate Ph. Eur. European Pharmacopoeia Phth Phthalic acid PTA Percutaneous Transluminal Angioplasty PMVE Perfluoromethyl vinyl ether PPM parts per million PTFE Polytetrafluoroethylene PVC Polyvinyl chloride R f Delay Factor rt room temperature SPDP N-Succinimidyl 3-(2-pyridyldithio)propionate TBDMS tert-Butyldimethylsilyl TBSOTf tert-Butyldimethylsilyl triflate TEA Triethylamine TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxyl TFE Tetrafluoroethylene THF Tetrahydrofuran TLC Thin Layer Chromatography TMB 3,3',5,5'-Tetramethylbenzidine TMS Trimethylsilyl TMSOTf Trimethylsilyl triflate Tol Toluene Tris Tris(hydroxymethyl)aminomethane, buffer solution p-TsOH para-toluenesulfonic acid USP United States Pharmacopeia VA Ventricle-atrium VP Ventriculoperitoneum
[0149] (Provisions) Provisions describing further embodiments of the present invention are as follows: 1. An anticoagulant surface, the surface having a plurality of heparin fragments covalently attached thereto, wherein the fragments consist of 5-18 saccharide units, and at least a portion of the plurality of fragments has polysaccharide sequence A: [ka] (Wherein, R=Ac or SO3 - is) Including, The anticoagulant surface, which surface catalyzes the inhibition of FIIa and FXa by AT. 2. The surface of clause 1, wherein said surface inhibits FIIa activity by at least 50% when measured according to evaluation method G. 3. The surface of any of clauses 1 or 2, wherein the structure of the heparin fragments is heterogeneous. 4. The surface according to any of clauses 1 or 2, wherein the structure of the heparin fragments is uniform and all contain the polysaccharide sequence A. 5. The surface of any one of clauses 1-4, wherein the fragment of heparin is a fragment of native heparin produced by a process comprising degrading native heparin. 6. The surface of any one of clauses 1-4, wherein said fragment of heparin is synthetically produced. 7. The surface of any one of clauses 1-6, wherein said heparin fragment is covalently attached to said surface via a linker. 8. The surface of any one of clauses 1-7, wherein the heparin fragment is single-point attached. 9. The surface of clause 8, wherein said heparin fragments are end point attached. 10. The surface according to clause 9, wherein the heparin fragment is covalently attached to the surface via its reducing end. 11. At least 1 pmol / surface cm for binding of AT, preferably measured according to Evaluation Method J. 2 , e.g., at least 2 pmol / cm of surface 2 , at least 3 pmol / surface cm 2 , at least 4 pmol / surface cm 2 , or at least 5 pmol / cm of surface 2 11. The surface of any one of clauses 1 to 10, having a heparin activity of 12. At least 1 μg / cm, preferably measured according to Evaluation Method H 2 , e.g., at least 2 μg / cm 2 , at least 4 μg / cm 2 , at least 5 μg / cm 2 , or at least 6 μg / cm 2 12. The surface of any one of clauses 1-11, having a heparin concentration of 13. The surface of any one of clauses 1 to 12, wherein the heparin fragment consists of at least 6 saccharide units. 14. The surface of any one of clauses 1 to 13, wherein the heparin fragment consists of 14 sugar units or less. 15. The linker is represented by formula (I) (I) (CH2) n NHCO(CH2) m (In the formula, n is 1 to 20, and m is 1 to 20.) 7. A surface as described in clause 7, including EXAMPLES
[0150] (Example) (General Procedure) (Evaluation method) When reaction mixtures were prepared in Evaluation Methods C through G below, the enzyme solutions (FXa and FIIa) were consistently added last, just prior to the start of the incubation.
[0151] (Evaluation Method A: Determination of Molecular Weight of Heparin Fragment Fraction) The molecular weight of the heparin fragment fraction is basically determined by the USP <209> The molecular weight of low molecular weight heparin is determined by analytical gel permeation chromatography (GPC) on a system consisting of two Superdex columns (S-75 and S-200) in series. The peak position is identified based on the elution profile of the second international standard of low molecular weight heparin (NIBSC, UK) for molecular weight calibration, where the most delayed peak of the standard is a disaccharide.
[0152] (Evaluation method B: Determination of heparin fragment concentration) The amount of isolated heparin fragments in the solution is estimated by analyzing the uronic acid content by carbazole assay linked to a heparin standard curve (Bitter, T.; Muir, HM, Anal. Biochem., 1962, (4), 330-334).
[0153] (Evaluation method C: Determination of anti-FXa activity of heparin fragments in solution compared to an international standard) The anticoagulant activity of heparin fragments is determined by the anti-FXa assay, which is essentially the same method as the USP 10001 standard for unfractionated and low molecular weight heparins. <208> The anti-FXa activity of heparin is measured according to the anti-FXa and anti-FIIa assays. The method is based on the ability of heparin to accelerate the antithrombin inhibition of FXa in vitro, where residual FXa activity is detected using a chromogenic FXa substrate (CS 11(65)). The results, expressed as IU / mg (International Units / mg), are calculated using the parallel line model against the second international standard of low molecular weight heparin.
[0154] (Evaluation method D: Determination of anti-FXa activity of heparin fragments in solution) A reaction mixture containing heparin fragments (final concentration of 0.2 mg / ml), AT (0.03 IU / ml), FXa (0.5 μg / ml), Tris (17 mM, pH 7.4), NaCl (60 mM), HSA (1 mg / ml), and PEG-6000 (2 mg / ml) is incubated at room temperature for time intervals of 0, 5, 10, 20, and 30 min essentially as in method C, and 250 μl of the reaction mixture is transferred to a test tube on ice. Residual FXa activity is then determined by transferring 150 μl of the incubated solution to a well in a microtiter plate containing 150 μl of chromogenic FXa substrate (CS 11(65), 0.5 mM). The absorbance at 405 nm is recorded kinetically in a plate reader for 2 min to give FXa activity as mOD / min (mean optical density / min).
[0155] (Evaluation method E: Determination of anti-FIIa activity of heparin fragments in solution) A reaction mixture containing heparin fragments (0.2 mg / ml) in a solution containing AT (0.02 IU / ml), FIIa (2.5 IU / ml), Tris (17 mM, pH 7.4), NaCl (60 mM), HSA (1 mg / ml), and PEG-6000 (2 mg / ml) is incubated at room temperature for time intervals of 0, 5, 10, 20, and 30 min essentially as in method C. The reaction mixture is transferred to a test tube on ice. Residual FIIa activity is then determined by transferring the incubated solution to a well in a microtiter plate containing a chromogenic FIIa substrate (CS 11 (38), 0.25 mM final concentration). The absorbance at 405 nm is recorded kinetically in a plate reader for 2 min to obtain FIIa activity as mOD / min (mean optical density / min).
[0156] (Evaluation method F: Determination of anti-FXa activity of immobilized heparin fragments) A loop is prepared from several lengths of tubing (16.5 cm, including 1.5 cm required to connect both ends with a short length of PE tubing with an internal diameter of 2 mm). An aliquot (1.5 mL) of a reaction mixture containing AT (0.03 IU / mL), FXa (0.5 μg / mL), Tris (17 mM, pH 7.4), NaCl (60 mM), HSA (1 mg / mL), and PEG-6000 (2 mg / mL) is transferred to the loop and circulated for 10 min. At the end of the incubation, the reaction mixture is transferred to a test tube in an ice bath, and 150 μl of the incubated solution is transferred to a well in a microtiter plate and mixed with 150 μl of FXa substrate (0.5 mM). Residual FXa activity is then determined essentially as in Evaluation Method D. As a negative control, the same reaction mixture is incubated in a test tube or loop of uncoated PVC tubing. Results were normalized to uncoated PVC and results are expressed as % inhibition of FXa.
[0157] (Evaluation method G: Determination of anti-FIIa activity of immobilized heparin fragments) A loop (15 cm) is prepared from several pieces of tubing (16.5 cm, including 1.5 cm needed to connect both ends with a short piece of PE tubing with an internal diameter of 2 mm). An aliquot of a reaction mixture containing AT (0.02 IU / mL), FIIa (2.5 IU / mL), Tris (17 mM, pH 7.4), NaCl (60 mM), HSA (1 mg / mL), and PEG-6000 (2 mg / mL) is transferred to the loop and circulated for 10 min. At the end of the incubation, the reaction mixture (250 μl) is transferred to a test tube in an ice bath. Residual FIIa activity is then determined essentially as in Evaluation Method E. As a negative control, the same reaction mixture was incubated in a test tube or in a loop of uncoated PVC tubing. The results were normalized to uncoated PVC and the results are expressed as % inhibition of FIIa.
[0158] (Evaluation method H: Quantification of heparin fragments immobilized on a surface (heparin density)) Quantification of the heparin immobilized on the surface is performed by complete degradation of heparin followed by colorimetric measurement of the reaction products released into solution. Degradation is achieved by reacting the heparin surface with excess sodium nitrite under acidic conditions. The degradation products, primarily disaccharides, are colorimetrically quantified by reaction with MBTH (3-methyl-2-benzothiazolinone hydrazine hydrochloride) essentially as described in Smith RL and Gilkerson E (1979), Anal Biochem 98, 478-480, which is incorporated herein by reference in its entirety.
[0159] (Evaluation method I: Toluidine blue staining test (heparin distribution)) Toluidine blue staining solution is used to assess heparin distribution. This solution is prepared by dissolving 200 mg of toluidine blue in 1 L of water. The specimen is subjected to the staining solution for 2 minutes and then thoroughly rinsed with water. Blue / violet staining indicates that the negatively charged heparin molecules are uniformly distributed in the outer coating layer.
[0160] (Evaluation method J: Heparin activity test (functionality of immobilized heparin)) For solid objects coated according to the process of the present invention, including a heparin fragment coating, the heparin activity of the solid object can be determined using the methods described in Pasche et al., "A binding of antithrombin to immobilized heparin under varying flow conditions" (Artif. Organs 1991; 15:281-491, incorporated herein by reference in its entirety) and Larsen M., "Assay of plasmaheparin using thrombin and the chromogenic substrate HD-Phe-Pip-Arg-pNA" (S-2238) (Thromb. Res. 1978; 13:285-288, incorporated herein by reference in its entirety). The ability or capacity of heparin to bind AT can be measured as described in L et al. The washed samples are incubated with excess antithrombin in solution to saturate all available antithrombin binding sites on the heparin surface. Non-specifically adsorbed antithrombin is rinsed off using a salt solution. Antithrombin specifically bound to the immobilized heparin is then released by incubation with a solution of high concentration of heparin. Finally, the antithrombin released from the heparin surface is measured with a thrombin inhibition assay based on a chromogenic thrombin substrate. The results are expressed as picomoles of bound AT per apparent square centimeter of the device (pmol AT / cm solid surface). 2) Apparent solid object surface area does not take into account multiple coated surfaces, nor the porosity of solid objects composed of porous materials. If the surface of a solid object is porous, the effect of porosity on the surface area is not taken into account for these calculations. For example, the apparent surface area of a cylindrical tubular ePTFE vascular graft (made of a porous material) containing heparin immobilized on a substrate material that includes the inner surface of the tubular graft is calculated as 2πrL, as for any cylindrical shape: where r is the inner radius of the graft; L is the axial length; and π is the number pi. This method can be used to measure the activity of any anticoagulant entity that has AT binding activity.
[0161] (Evaluation method K: Molecular weight of dextran sulfate in solution (molecular weight of anionic polymer)) The molecular weight determination of dextran sulfate samples is performed on a gel permeation chromatography (GPC) instrument. The dextran sulfate samples are dissolved in an aqueous elution medium and analyzed on a GPC instrument suitable for the molecular weight range of 1,000 Da to 100,000 Da (Sepharose column) or 100,000 Da to 2,000,000 Da (Sephacryl column). Dextran sulfate standards of appropriate molecular weight are used to verify the accuracy of the calibration curve. Polymers such as dextran sulfate are disperse molecules, i.e., they have a distribution of molecular weights that can be described with various molecular weight averages. The commonly reported value is the weight average molecular weight (Mw). See Odian G., Principles of Polymerization, 3rd Edition, Section 1.4, Molecular weight, p. 24 (incorporated herein in its entirety) which describes the theory of determining the molecular weight of polymers using GPC techniques. The molecular weights of anionic polymers other than dextran sulfate can be determined using this method.
[0162] (Evaluation method L: Solution charge density of dextran sulfate in solution (solution charge density of anionic polymer)) Quantitative determination of charge density is carried out on a Mutek particle charge detector by titration of polyelectrolyte solutions (0.001M) (polydiallyldimethylammonium chloride (Poly-Dadmac) and polyethylene sodium sulfate (PES-Na)). Samples are dissolved in water to a concentration of 0.06 g / L (maximum viscosity allowed 6000 mPas). For all sample solutions, the pH is adjusted to 3. 10 mL per sample solution is added for each measurement, after which the appropriate polyelectrolyte solution is titrated at intervals of 1 unit per 3 seconds. See S. Farris et al., Charge Density Quantification of Polyelectrolyte Polysaccharides by Conductometric Titration: An Analytical Chemistry Experiment, J. Chem. Educ., 2012, 89(1), pp 121-124, incorporated herein by reference in its entirety. The solution charge density of anionic polymers other than dextran sulfate can be determined using this method.
[0163] Preliminary Examples and Testing Preparation of a Synthetic Pentasaccharide Incorporating a Terminal Linker (General Procedure) Unless otherwise noted, reactions were carried out under an inert atmosphere of nitrogen in oven-dried glassware with magnetic stirring and rigorous exclusion of air and moisture. Air- and moisture-sensitive reagents were transferred using N2-flushed stainless steel cannulas or plastic syringes. Oxygen-free nitrogen was obtained from BOC Gas. Evaporation in vacuum refers to removal of volatiles on a Buchi rotary evaporator with built-in vacuum pump. Silica gel chromatography was performed using Davisil LC60A SiO2 (40-63 μm) silica gel. All reactions were monitored by thin layer chromatography (TLC). TLC was performed on Merck DC-Alufolien plates pre-coated with Silica Gel 60 F254. These were visualized using UV light (254 nm) fluorescence quenching and / or by charring with an 8% H2SO4 soak (stock solution: 8 mL concentrated H2SO4, 92 mL EtOH) and / or a ninhydrin soak (stock solution: 0.3 g ninhydrin, 3 mL AcOH, 100 mL EtOH).
[0164] (material) The two disaccharide intermediates I.63 and I.66 were purchased from Heparin Building Blocks. All other synthesis chemicals were purchased from commercial suppliers (Acros, Carbosynth Ltd, Fischer Scientific Ltd, Merck, Sigma-Aldrich Corp, and VWR) and used without further purification. Anhydrous CHCl, EtO, and THF reaction solvents were obtained from a PureSolv-EN™ solvent purification system. All other anhydrous solvents were used as purchased from Sigma-Aldrich in AcroSeal® bottles.
[0165] (device) 1H NMR spectra were recorded on a 400 MHz Varian-Inova spectrometer, a 500 MHz Varian-Inova spectrometer, or a 600 MHz Varian-Inova spectrometer. 13 C NMR spectra were recorded on a 400 MHz Varian-Inova spectrometer (101 MHz), a 500 MHz Varian-Inova spectrometer (126 MHz), or a 600 MHz Varian-Inova spectrometer (151 MHz). Chemical shifts (δ) are reported in parts per million (ppm). 1 H NMR spectra were normalized to the residual solvent peaks CDCl3 (δ=7.26 ppm); CD3OD (δ=3.31 ppm); D2O (δ=4.79 ppm); or internal TMS (δ=0.00 ppm). 13 C NMR spectra were normalized to the residual solvent peak CDCl3 (δ = 77.16 ppm); or CD3OD (δ = 49.00 ppm). 13 All C NMR 1 H decoupled. All NMR data are expressed as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = double doublet, m = multiplet), coupling constant in Hertz (Hz), integral. Assignments are homonuclear ( 1 H- 1 H) (COSY) and heteronuclear ( 1 H- 13 C) (HSQC, HMBC) assisted by two-dimensional correlation spectroscopy. High-resolution mass spectrometry (HRMS) experiments were recorded on a Waters micromass LCT LC-Tof instrument using electrospray ionization (ESI) in either positive or negative mode.
[0166] Example 1: Synthesis of a synthetic pentasaccharide with terminal attachment linkers incorporated at the reducing and non-reducing ends (Example 1.1: 5-aminopentyl 2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl-(1→4)-β-D-glucopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-3,6-di-O-sulfo-α-D-glucopyranosyl-(1→4)-2-O-sulfo-α-L-idopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-6-O-sulfo-β-D-glucopyranoside) [ka] A schematic of the synthetic route for this molecule is shown in FIG.
[0167] (i) Synthesis of monosaccharide building block B [ka] Scheme 1. Reagents and conditions: synthesis of intermediate I.9. a) EtSH, BF3·Et2O, anhydrous CH2Cl2, 0 °C → rt, 1.5 h, 90%; b) CH3ONa, CH3OH, rt, 1 h, quantitative; c) PhCH(OMe)2, CSA, anhydrous CH3CN, rt, overnight, 75%; d) BnBr, NaH, DMF, 0 °C → rt, 2 h, 80%; e) AcOH 70%, 80 °C, 1.5 h, 90%; f) TEMPO, BAIB, CH2Cl2 / H2O 3:1, rt, 1 h, 65%; g) (CH3)3SiCHN 2、 anhydrous CH3OH / toluene 1 / 1, 0°C, 5 min, 90%; h) ClCH2COCl, anhydrous pyridine, anhydrous CH2Cl 2、 0°C, 15 min, 90%; i) Br2, anhydrous CH2Cl2, 0°C→rt, 45 min, dark, 90%;
[0168] (Ethyl 4,6-O-benzylidene-1-thio-β-D-glucopyranoside, intermediate I.3) [ka] Commercially available 1,2,3,4,6-penta-O-acetyl-β-D-glucopyranose (I.1, 20.0 g, 0.05 mol, 1 equiv.) was dissolved in anhydrous CHCl (100 mL, 0.5 M) and ethanethiol (5.4 mL, 0.075 mol, 1.5 equiv.) was added under nitrogen atmosphere. The solution was cooled to 0° C. and boron trifluoride etherate (12.3 mL, 0.1 mol, 2 equiv.) was added slowly and the reaction was allowed to reach room temperature. After 1 h, TLC (cyclohexane / ethyl acetate 1:1) showed complete conversion of starting material to product. The reaction was placed on ice and quenched with TEA. The solvent was evaporated and the crude was purified by flash chromatography with cyclohexane / ethyl acetate (80 / 20→60 / 40) to give intermediate I.2 (18.8 g, 0.048 mol, 96%) as a white solid (R f (cyclohexane / ethyl acetate 6:4) 0.48. 1 H NMR is consistent with literature J. Am. Chem. Soc., 2013, 135(45), 16895-16903).
[0169] Intermediate I.2 was dissolved in methanol (100 mL, 0.5 M) and sodium methoxide powder (0.5 g, 0.01 mol, 0.2 equiv.) was added. The reaction was stirred at room temperature overnight (TLC cyclohexane / ethyl acetate 1:1; dichloromethane / methanol 8:2). The reaction was then rinsed with the acidic resin DOWEX H + The resulting deprotected sugar (10.7 g, 0.048 mol, 1 equiv.) was dissolved in anhydrous DMF (100 mL, 0.5 M) and benzaldehyde dimethyl acetal (14.3 mL, 0.096 mol, 2 equiv.) and camphor-10-sulfonic acid (5.6 g, 0.024 mol, 0.5 equiv.) were added. The reaction was stirred at 50° C. overnight, then placed on ice and quenched with TEA to pH 7. The solvent was evaporated under reduced pressure and the crude was purified by flash chromatography using cyclohexane / ethyl acetate (50 / 50→30 / 70) to give intermediate I.3 (12.6 g, 0.04 mol, 84%) as a white solid (R f(cyclohexane / ethyl acetate 1:1) 0.35. [ka] This is consistent with the literature, Carbohydrate Research, 1992, 225, 229-245.
[0170] (Ethyl 2,3-di-O-benzyl-4,6-O-1-thio-β-D-glucopyranoside, intermediate I.5) [ka] A solution of intermediate I.3 (4.28 g, 13.7 mmol, 1 equiv) in anhydrous DMF was cooled to 0° C. and NaH (60% in oil, 1.64 g, 68.5 mmol, 5 equiv) was added. The suspension was stirred at 0° C. for 10 min, after which benzyl bromide (6.3 mL, 54.8 mmol, 4 equiv) was added. The reaction was stirred at room temperature for 1 h. TLC (cyclohexane / ethyl acetate 1:1) showed complete conversion of starting material to product. The reaction was placed on ice and quenched with methanol (~15 mL) and water (~30 mL). The whole was diluted with EtOAc (250 mL) and extracted. The organic layer was washed with water (2×200 mL), dried over MgSO4, and evaporated. The residue was dissolved in EtOH and the resulting precipitate, intermediate I.4 (5.96 g, 12.1 mmol, 88%), was filtered and used in the next step without further purification (R f (cyclohexane / ethyl acetate 9:1) 0.35. 1 1 H NMR is consistent with the literature, Carbohydrate Research, 1992, 225, 229-245).
[0171] A solution of intermediate I.4 (2.4 g, 4.8 mmol, 1 equiv.) in 70% aqueous AcOH (25 mL) was refluxed at 80° C. for 4 h (TLC cyclohexane / ethyl acetate 7:3). The solution was concentrated and the resulting residue was purified by automated flash chromatography using cyclohexane / ethyl acetate (90 / 10→20 / 80) to give intermediate I.5 (1.6 g, 3.9 mmol, 81%) (Rf (cyclohexane / ethyl acetate 4:6) 0.46. [ka] This is consistent with the literature Journal of Organic Chemistry, 2013, 78(9), 4319 - 4328.
[0172] (Methyl(ethyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranoside)uronate, intermediate I.7) [ka] To a vigorously stirred solution of intermediate I.5 (1.6 g, 3.9 mmol, 1 equiv.) in 2:1 CH2Cl2 / H2O (30 mL) was added TEMPO (0.2 g, 0.78 mmol, 0.2 equiv.) and BAIB (3.1 g, 9.7 mmol, 2.5 equiv.). Stirring was allowed until TLC (CH2Cl2 / CH3OH 9:1 + 1% AcOH) showed complete conversion of starting material to a lower migration spot (~45 min). The reaction mixture was quenched by the addition of 10 ml of Na2S2O3 solution (10% in H2O). The aqueous phase was acidified to pH 2 with 1M HCl, and the mixture was then extracted twice with CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and concentrated. Flash column chromatography using cyclohexane / ethyl acetate (1:1 + 1% AcOH) afforded the pure glucuronic acid I.6 (1.04 g, 2.48 mmol, 63%) as a white foam (R f (Cyclohexane / Ethyl acetate (1:1 + 1% AcOH) 0.52. 1 1 H NMR is consistent with the literature Organic Letters, 2004, vol. 6, 13, 2165-2168).
[0173] Intermediate I.6 (1.03 g, 2.4 mmol, 1 equiv.) was dissolved in 1:1 anhydrous methanol / anhydrous toluene (12 mL, 0.2 M) and the solution was cooled to 0° C. 2M Me3SiCHN2 in diethyl ether-trimethylsilyldiazomethane- (1.5 mL, 2.9 mmol, 1.2 equiv.) was added. After 5 min, TLC analysis (cyclohexane / ethyl acetate 1:1 + 1% AcOH) indicated the formation of the product. The reaction was quenched by the addition of acetic acid and evaporated. The resulting residue was purified by automated flash chromatography using 80 / 20 cyclohexane / ethyl acetate to give intermediate I.7 (0.945 g, 2.2 mmol, 90%) as a colorless oil (R f (cyclohexane / ethyl acetate 6:4) 0.48. [ka] This is consistent with Organic Letters, 2004, vol. 6, 13, 2165-2168.
[0174] (Methyl (2,3-di-O-benzyl-4-O-chloroacetyl-α-D-glucopyranosyl bromide)uronate, intermediate I.9) [ka] A solution of intermediate I.7 (0.800 g, 1.85 mmol, 1 equiv.) in anhydrous CHCl (18 mL, 0.1 M) was cooled to 0° C. and anhydrous pyridine (3.0 mL, 37.0 mmol, 20 equiv.) and chloroacetyl chloride (0.3 mL, 3.7 mmol, 2 equiv.) were added. The reaction was stirred at 0° C. for 10 min, after which TLC (cyclohexane / ethyl acetate 6:4) showed complete conversion of starting material to product. The reaction was diluted with CHCl and washed with 1 M HCl, saturated aqueous NaHCO, and brine. The organic phase was dried over MgSO, filtered, and evaporated. The crude was purified by flash chromatography using 8:2 cyclohexane / ethyl acetate to give pure intermediate I.8 (0.860 g, 1.68 mmol, 91%) as a white solid (Rf (cyclohexane / ethyl acetate 8:2) 0.38. 1 H NMR and 13 C NMR is consistent with the literature: Carbohydrate Research, 2003, 338, 23, 2605 - 2609).
[0175] To a solution of intermediate I.8 (860 mg, 1.68 mmol, 1 equiv.) in anhydrous CHCl (17 mL, 0.1 M) was added bromine (0.095 mL, 1.85 mmol, 1.1 equiv.). The reaction was stirred in the dark at room temperature for 1 h, then quenched with cyclohexene and evaporated in vacuo. The crude was purified by flash chromatography using 8:2 cyclohexane / ethyl acetate to give pure intermediate I.9 (822 mg, 1.55 mmol, 92%) as an oil (R f (cyclohexane / ethyl acetate 8:2) 0.39. [ka] ESI-MS: C 23 H 25 Calculated value of BrClO7[M]: 527.05, Found value: 550.60[M+Na + ]).
[0176] (ii) Synthesis of monosaccharide building block C [ka] Scheme 2. Reagents and conditions: synthesis of intermediate I.16. a) CH3OH / H2O / TEA 10:10:1, rt, 1.5 h, quantitative; b) step I: bis(tributylstannyl)oxide, anhydrous CH3CN, molsieves 3Å, 80°C, 3 h, step II: iodine, rt, 1 h, 65%; c) NaN3, DMF / H2O 9:1, 120°C, overnight, 70%; d) TBDMSCl, imidazole, DMF, rt, overnight, 65%; e) Ac2O, Py, rt, overnight, 90%; f) 70% AcOH, 80°C, overnight, 75%.
[0177] (1,6-anhydro-2-deoxy-2-iodo-β-D-glucose, intermediate I.12) [ka] A solution of commercially available tri-O-acetyl-D-glucal (I.10, 25.0 g, 91.8 mmol, 1 equiv.) in 10:10:1 CH3OH / H2O / TEA (210 mL) was stirred at room temperature for 2 h. TLC (CH2Cl2 / CH3OH 9:1) showed complete conversion of starting material to intermediate I.11. The solution was concentrated under vacuum and dried over Schlenck overnight. The crude was used directly in the next step without further purification.
[0178] Intermediate I.11 was treated with bis-tri-n-butyltin oxide (37.4 mL, 73.4 mmol, 0.8 equiv.) and freshly activated powdered 3 Å molecular sieves in refluxing anhydrous acetonitrile under N2 for 3 h. The mixture was cooled to 5 °C, iodine (35 g, 137.7 mmol, 1.5 equiv.) was added, and the mixture was stirred at room temperature for 2 h (TLC CH2Cl2 / CH3OH 9:1). The mixture was filtered through Celite and the solvent was concentrated. Saturated aqueous Na2S2O3 and cyclohexane (1:1, 300 mL) were added to the crude, and the biphasic mixture was stirred overnight. The aqueous phase was extracted with ethyl acetate (500 mL x 3). The organic layer was dried over MgSO4, filtered, and concentrated. Purification by chromatography with toluene / acetone (95 / 5→60 / 40) afforded I.12 (11.7 g, 43.0 mmol, 58%) as a white solid (R f (toluene / acetone 7:3) 0.42. [ka] This is consistent with the literature in Macromolecules 2002, 35, 3402-3412.
[0179] 1,6-Anhydro-2-azido-2-deoxy-4-O-(tert-butyldimethylsilyl)-β-D-glucose, intermediate I.14 [ka] Intermediate I.12 (4.0 g, 15.0 mmol, 1 equiv.) was dissolved in DMF / HO 9:1 (30 mL, 0.5 M) and sodium azide (3.9 g, 60.0 mmol, 4 equiv.) was added. The reaction was stirred at 120° C. for 4 h. TLC (toluene / acetone 7:3) showed complete conversion of starting material to product. The solvent was evaporated and the residue was purified by chromatography with toluene / acetone (95 / 5→60 / 40) to give I.13 (2.18 g, 11.6 mmol, 78%) as a white solid (R f (toluene / acetone 7:3) 0.39. [ka] This is consistent with the literature, Tetrahedron Letters, 2001, 42, 6487-6489.
[0180] To a solution of intermediate I.13 (2.07 g, 11.1 mmol, 1 equiv.) in DMF (20 mL, 0.5 M) was added imidazole (2.0 g, 13.3 mmol, 1.2 equiv.) and tert-butyldimethylsilyl chloride (1.5 g, 22.2 mmol, 2 equiv.). After stirring at room temperature overnight, the solvent was evaporated in vacuo and the crude was purified by chromatography with cyclohexane / ethyl acetate (95 / 5→60 / 40) to give intermediate I.14 (2.25 g, 7.4 mmol, 67%) as a colorless oil (R f (cyclohexane / ethyl acetate 7:3) 0.4. [ka]
[0181] (1,6-anhydro-3-O-acetyl-2-azido-2-deoxy-β-D-glucose, intermediate I.16) [ka] Intermediate I.14 (7.29 g, 24.2 mmol, 1 equiv.) was dissolved in pyridine (100 mL, 0.25 M) and acetic anhydride (22 mL, 10 equiv.) was added. The reaction was stirred at room temperature overnight, after which the excess acetic anhydride was quenched with methanol and the mixture was evaporated. The crude was purified by chromatography using cyclohexane / ethyl acetate (95 / 5 to 60 / 40) to give intermediate I.15 (7.68 g, 22.3 mmol, 92%) as a white solid (R f (cyclohexane / ethyl acetate 7:3) 0.44. 1 H NMR and 13 C NMR is in agreement with literature J. Org. Chem. 1997, 62, 992-998).
[0182] Intermediate I.15 (3.0 g, 8.7 mmol, 1 equiv.) was dissolved in 70% aqueous acetic acid (120 mL) and heated at 80° C. overnight. TLC (cyclohexane / ethyl acetate 6:4) showed complete conversion of starting material to product. The solvent was evaporated and the crude was purified by automated chromatography with cyclohexane / ethyl acetate (95 / 5→60 / 40) to give intermediate I.16 (1.58 g, 6.9 mmol, 80%) as an oil (R f (cyclohexane / ethyl acetate 4:6) 0.35. [ka] ESI-MS: calculated value for C8H11N3O5 [M]: 229.07, found 251.23 [M+Na+]; 479.90 [2M+Na+], 1H NMR and 13C NMR are in agreement with literature J. Org. Chem. 1997, 62, 992-998).
[0183] (iii) Synthesis of monosaccharide building block A [ka] Scheme 3. Reagents and conditions: synthesis of intermediate I.20. a) BnBr, NaH, DMF, 0°C→rt, 1 h, 85%; b) Ac2O, TBSOTf, 0°C, 10', 85%; c) EDA, AcOH, THF, rt, overnight, 75%; d) Cl3CCN, DBU, anhydrous CH2Cl2, 3 h, rt, 85%.
[0184] (1,6-O-Diacetyl-2-azido-3,4-di-O-benzyl-2-deoxy-glucopyranoside, intermediate I.18) [ka] Intermediate I.13 (500 mg, 2.7 mmol, 1 equiv.) was dissolved in anhydrous DMF (13.5 mL, 0.2 M) and the solution was cooled to 0 °C. NaH (324 mg, 13.5 mmol, 5 equiv.) was added, followed after 10 min by BnBr (1.3 mL, 10.8 mmol, 4 equiv.). After 30 min, TLC (cyclohexane / ethyl acetate 4:6) showed the formation of the product. The reaction was quenched with methanol and water. The mixture was poured into a separatory funnel and extracted with CHCl (×3). The collected organic phases were dried over MgSO and evaporated. The crude was purified by automated chromatography with cyclohexane / ethyl acetate (95 / 5→70 / 30) to give intermediate I.17 (846 mg, 2.3 mmol, 85%) as an oil (R f (cyclohexane / ethyl acetate 3:7) 0.55. [ka]
[0185] Intermediate I.17 (846 mg, 2.3 mmol, 1 equiv.) was dissolved in acetic anhydride (5 mL, 0.5 M) and the solution was cooled to 0° C. TBSOTf was added and the reaction was checked by TLC (cyclohexane / ethyl acetate 8:2) after 10 min, which showed product formation. The reaction was quenched with TEA and concentrated in vacuo. The crude was purified by automated flash chromatography using cyclohexane / ethyl acetate (90:10 to 60:40) to give intermediate I.18 (930 mg, 2.0 mmol, 87%) in an α / β mixture as a white foam (R f (cyclohexane / ethyl acetate 8:2) 0.35. [ka] ESI-MS: C 24 H 27 Calculated value of N3O7[M]: 469.18, Found value: 492.04[M+Na + ]; 961.22[2M+Na + ]).
[0186] (6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl trichloroacetimidate, intermediate I.20) [ka] Intermediate I.18 (400 mg, 0.85 mmol, 1 equiv.) was dissolved in THF (8.5 mL, 0.1 M) and ethylediamine (87 μl, 1.3 mmol, 1.5 equiv.) and acetic acid (74 μl, 1.3 mmol, 1.5 equiv.) were added. The reaction was stirred at room temperature overnight, after which it was diluted with CHCl and washed with 1 M HCl. The aqueous phase was extracted twice with CHCl. The combined organic layers were washed with aqueous saturated NaHCO and brine, dried over MgSO and evaporated. The crude was purified by automated chromatography (cyclohexane / ethyl acetate 85 / 15 to 40 / 60) to give intermediate I.19 (347 mg, 0.81 mmol, 95%) as a white wax (R f(cyclohexane / ethyl acetate 6:4) 0.40. [ka]
[0187] Trichloroacetonitrile (0.812 mL, 8.1 mmol, 10 equiv.) and DBU (24 μL, 0.162 mmol, 0.2 equiv.) were added to a solution of intermediate I.19 (347 mg, 0.81 mmol, 1 equiv.) in anhydrous CHCl (8 mL, 0.1 M) and the reaction mixture was stirred at room temperature under Ar for 2 h. After concentration, the residue was purified by flash chromatography eluting with cyclohexane / ethyl acetate (8:2 + 1% TEA) to give I.20 (439 mg, 95%) as the 90% α anomer (R f (cyclohexane / ethyl acetate 6:4) 0.52. [ka] This is consistent with the literature Carbohydrate Research 2003, 338, 1369-1379.
[0188] (iv) Synthesis of monosaccharide building block D [ka] Scheme 4 Reagents and conditions: Synthesis of intermediate I.32. a- NaH, BnBr, THF, 0°C → rt, b) 2 h; H2O / AcOH, 40°C, overnight, 79% (2 steps); c) MsCl, pyridine, 0 → 4°C, overnight, 98%; d) KOAc, 18-crown-6, MeCN, 92°C, 24 h, 89%; e) CH2Cl2, t BuOK, tBuOH, 0 °C, overnight, 89%; f) dioxane, 2M H2SO4, 100 °C, overnight, 45%; g) pyridine, Ac2O, 0 °C → rt, overnight 91%; h) TMSOTf, CH2Cl2, Ac2O, 0 °C, 20 min, 87%; i) BF3·Et2O, HSPh, CH2Cl2, 0 °C → rt, 4 h, 90%; j) MeOH, NaOMe, rt, overnight, 92%; k) CSA, DMF, naphthyl dimethyl acetal, 60 °C, overnight, 84%; l) BzCl, pyridine, 0 °C → rt overnight, 89%.
[0189] (3-O-benzyl-1,2-O-isopropylidene-α-D-glucofuranose, intermediate I.22) [ka] Commercially available diacetone glucose I.21 (20 g, 76.84 mmol, 1 equiv) was dissolved in anhydrous THF (150 mL) and cooled to 0 °C. 60% NaH (5.1 g, 126.8 mmol, 1.65 equiv) was added and the mixture was stirred for 30 min. BnBr (13.7 mL, 115.3 mmol, 1.5 equiv in 14 mL anhydrous DMF) was then added slowly and the mixture was allowed to warm back to rt and stirred for 2 h, after which TLC showed no remaining starting material. The mixture was cooled to 0 °C and the reaction was quenched by the slow addition of MeOH (264 mL, 6500 mmol, 85 equiv) and stirred on ice for an additional 10 min. The solvent was concentrated and the resulting residue was dissolved in CHCl and washed successively with HO and brine. The aqueous extract was re-extracted with additional CHCl. The combined organic layers were washed with brine, then dried over MgSO4, filtered, and concentrated to give a yellow syrup, which was used directly without further purification. The crude was dissolved in H2O:AcOH solution (96 mL 1:1 v / v) and stirred at 45 °C for 4.5 h, then heated to 50 °C for 1 h. As the conversion was still incomplete, an additional 48 mL H2O was added and the reaction was stirred at 40 °C overnight. The reaction was then neutralized by careful addition of saturated aqueous K2CO3 solution, transferred to a separatory funnel, and extracted three times with CHCl2. The combined organics were washed twice with brine, dried over Na2SO4, filtered, and concentrated to give a yellow syrup, which was purified by column chromatography (Tol / EtOAc 8-66%) to give intermediate I.22 (18.33 g (59.06 mmol, 77% for two steps) as a yellow syrup) (R f :(Tol / EtOAc 2:1 v / v) 0.15. [ka]
[0190] (3-O-benzyl-1,2-O-isopropylidene-5,6-di-O-methanesulfonyl-α-D-glucofuranose, intermediate I.23) [ka] Intermediate I.22 (18.33 g, 58.97 mmol, 1 equiv) was dissolved in anhydrous pyridine (88 mL), cooled to 0° C. and stirred at that temperature for 5 min, after which MsCl (11 mL, 141.53 mmol, 2.4 equiv) was added slowly. The mixture was stirred at that temperature for 30 min, then warmed to 4° C. and stirred overnight. The next day, additional MsCl (2 mL, 25.88 mmol, 0.44 equiv) was added and the reaction was kept stirred at 4° C. for 2 h, then poured into H2O (500 mL, 50° C.), which resulted in the formation of a precipitate. The mixture was allowed to cool to rt and stand overnight. The solid was collected by filtration, washed with HO, then coevaporated twice with toluene and dried to give intermediate I.23 (26.2 g, 58.68 mmol, 98%) as a white solid (Rf: (cyclohexane / EtOAc, 3:2 v / v) 0.31. [ka]
[0191] (6-O-acetyl-3-O-benzyl-1,2-O-isopropylidene-5-O-methanesulfonyl-α-D-glucofuranose, intermediate I.24) [ka] Intermediate I.23 (19.7 g, 42.23 mmol, 1 equiv), anhydrous KOAc (41.44 g, 422.3 mmol, 10 equiv), and 18-crown-6 (1.11 g, 4.22 mmol, 0.1 equiv) were dissolved in MeCN (350 mL) and heated at 92 °C for 24 h, at which time TLC indicated consumption of starting material. The reaction mixture was cooled back to rt, filtered, and rinsed with additional MeCN. The filtrate was concentrated and the resulting residue was dissolved in CHCl and washed twice with water. The combined aqueous extracts were extracted with additional CHCl and the combined organic layers were dried over MgSO, filtered, and concentrated. The resulting solid was recrystallized from EtOH to give crystals that were isolated by filtration and washed three times with cold EtOH to give Intermediate I.24 (16.1 g, 37.4 mmol, 89%) as white crystals (R f : 0.61 (cyclohexane / EtOAc, 3:2 v / v) [ka]
[0192] (5,6-anhydro-1,2-O-isopropylidene-3-O-benzyl-β-L-idofuranose, intermediate 1.25) [ka] Intermediate I.24 (16.1 g, 37.43 mmol, 1 equiv.) was dissolved in anhydrous CH2Cl2 (170 mL) and t BuOK (8.4 g, 74.86 mmol, 2 equiv.) and t BuOH (80.5 mL, 842.18 mmol, 22.5 equiv) was added at 0° C. and the mixture was stirred at that temperature overnight. The next day, additional anhydrous tBuOK (1.5 g, 13.34 mmol, 0.36 equiv) was added and the reaction was stirred for an additional 4 h before being diluted with HO and CH2Cl2 and transferred to a conical flask. The mixture was carefully neutralized by slow addition of AcOH. The layers were then separated and the aqueous layer was extracted once with CH2Cl2. The combined organic layers were washed once with brine, dried over MgSO4, filtered and concentrated. The resulting brown oil was purified by chromatography through a short plug of silica with cyclohexane / EtOAc (3:2) to afford intermediate I.25 (9.76 g (33.39 mmol, 89%) as a yellow syrup (R f :(cyclohexane / EtOAc, 3:2 v / v) 0.6. [ka]
[0193] 2,4-Di-O-acetyl-1,6-anhydro-3-O-benzyl-β-L-idopyranose, intermediate I.27 [ka] Intermediate I.25 (8.5 g, 29.1 mmol, 1 equiv) was dissolved in a solution of 1,4-dioxane:2M H2SO4 (36 mL, 1:1 (v / v)) and refluxed at 100 °C overnight. The next day, the reaction was cooled back to rt and neutralized by the addition of saturated aqueous Ba(OH)2·8H2O, the solids were removed by filtration and washed with H2O and EtOAc. The layers were separated, the aqueous layer was extracted three more times with EtOAc, and the combined organic layers were washed once with H2O, dried over MgSO4, filtered, and concentrated. The resulting residue was recrystallized from EtOH to give intermediate I.26 as a yellow solid. The mother liquor was purified by flash chromatography (cyclohexane / EtOAc 10-80%) to give additional I.26 as a yellow solid for a total of 3.3 g (13.1 mmol, 45%) (R f : 0.17 (cyclohexane / EtOAc, 3:2 v / v). 1 H NMR and 13C NMR is consistent with literature Carbohydr. Res. 2008, 343(4), 596-606. Intermediate I.26 (2.87 g, 11.38 mmol, 1 equiv) was dissolved in anhydrous pyridine (23 mL) and cooled on ice. Ac2O (15 mL) was added slowly and the reaction was allowed to warm back to rt and stirred overnight. The next day the reaction was placed back on ice, quenched with H2O (30 mL) and diluted with CHCl2 (120 mL). It was then washed sequentially with 2M HCl, saturated aqueous NaHCO3, H2O, and brine. The organic layer was dried over MgSO4, filtered, concentrated, and the residue was purified by flash chromatography (cyclohexane / EtOAc 8-66%) to give intermediate I.27 (3.47 g, 10.3 mmol, 91%) as a yellow solid (R f :(cyclohexane / EtOAc, 3:2 v / v) 0.37. [ka]
[0194] (Phenyl 2,4,6-tri-O-acetyl-3-O-benzyl-1-thio-α-L-idopyranoside, intermediate I.29) [ka] Intermediate I.27 (300 mg, 0.89 mmol, 1 equiv) was dissolved in anhydrous CH2Cl2 (5 mL) and placed on ice. Ac2O (2 mL) was then added followed by TMSOTf (15 μL, 0.083 mmol, 0.09 equiv) under N2. The reaction was stirred on ice for 5 min and then warmed back to rt. After 20 min, TLC showed consumption of starting material and the appearance of two new spots R f The formation of 0.40 and 0.33 (Tol:EtOAc, 2:1 v / v) was indicated and the reaction was quenched by addition of NEt. The solvent was removed and the resulting syrup was purified by flash chromatography (Tol / EtOAc 8-66%) to give the anomeric mixture of tetraacetate I.28 (340 mg, 0.78 mmol, 87%), which was used without further characterization.
[0195] Intermediate I.28 (333 mg, 0.76 mmol, 1 equiv) was dissolved in anhydrous CHCl (7 mL) and placed on ice. HSPh (90 μL, 0.84 mmol, 1.1 equiv) was added and the mixture was stirred for 5 min before BF·EtO (0.28 mL, 2.28 mmol, 3 equiv) was added. The reaction mixture was allowed to warm back to rt and stirred for 3 h before additional BF·EtO (0.15 mL, 1.22 mmol, 1.6 equiv) was added at rt. Upon completion, the reaction was placed on ice, quenched with 5 mL of saturated aqueous NaHCO and the layers were separated. The organic layer was washed with HO, dried over MgSO, filtered and concentrated. The resulting residue was purified by flash chromatography (Tol / EtOAc 5-40%) to give I.29 (335 mg, 0.69 mmol, 90%) as a slightly orange syrup (R f : 0.67 (Tol / EtOAc, 2:1 v / v) [ka]
[0196] (Phenyl 3-O-benzyl-1-thio-α-L-idopyranoside, intermediate I.30) [ka] Intermediate I.29 (890 mg, 1.82 mmol, 1 equiv) was dissolved in anhydrous MeOH (9 mL), freshly prepared NaOMe was added, and the mixture was stirred at rt overnight. The next day, the reaction was quenched by the addition of DOWEX 50 WX8 acid resin, filtered, and washed with additional MeOH. The filtrate was concentrated to give I.30 (606 mg, 1.67 mmol, 92%) as a yellow foam. [ka]
[0197] (Phenyl 2-O-benzoyl-3-O-benzyl-4,6-O-(1-naphthyl)methylidene-1-thio-α-L-idopyranoside, intermediate I.32) [ka] Intermediate I.30 (1.55 g, 4.38 mmol, 1 equiv.) was dissolved in 20 mL of anhydrous CHCl, and the flask was covered with foil to protect from light. Then ZnI (2.78 g, 17.5 mmol, 2 equiv., dried for 8 h in the dark) was added followed by TMSSPh (2.5 mL, 13.1 mmol, 3 equiv.) at room temperature. The reaction was stirred overnight. The next day, TLC showed that the starting material had disappeared and two new spots had appeared. The reaction mixture was filtered through a pad of Celite, and the pad was washed with CHCl until the filtrate was clear. H0 (5 mL) and 9M HCl (15 mL) in 1,4 dioxane (5 mL) were added to the filtrate, and the mixture was stirred vigorously at room temperature until TLC showed the disappearance of the higher spot. The layers were separated and the organic layer was washed with 2M HCl, saturated aqueous NaHCO3 solution, and HO. It was then dried over MgSO4, filtered, concentrated, and the resulting syrup was purified by column chromatography using 4:1→1:1 (cyclohexane / EtOAc) to afford intermediate I.31 (1.56 g, 3.34 mmol, 75%) as a white foam ( 1 H NMR is consistent with literature J. Org. Chem. 2013, 78(14), 6911-6934).
[0198] Intermediate I.31 (390 mg, 0.84 mmol, 1 equiv.) was dissolved in 2.5 mL of anhydrous DMF, camphorsulfonic acid (136 mg, 0.59 mmol, 0.7 equiv.) and benzaldehyde dimethyl acetal (0.4 mL, 2.51 mmol, 3 equiv.) were added, and the mixture was then heated to 60° C. and stirred overnight. The next day, the reaction was cooled to room temperature and placed on ice before being quenched with NEt3. The solvent was removed in vacuo and the crude was coevaporated twice with cyclohexane. The crude was purified with 4:1→2:1 cyclohexane / ethyl acetate to give intermediate I.32 (360 mg, 0.65 mmol, 78%) as a white foam. [ka] This is consistent with the literature Carbohydr. Res. 2008, 343(4), 596-606.
[0199] (v) Synthesis of monosaccharide building block E [ka] Scheme 5 Reagents and conditions: Synthesis of intermediate I.41. a) MeOH / H2O, NaOH, NaHCO3, phthalic anhydride, rt, 3 h; b) pyridine, Ac2O, 0 °C → rt, overnight, 47% (2 steps); c) HSEt, TMSOTf, Cl CH2CH2Cl, 0 → rt → 40 °C, 5 h, 86%; d) MeOH, NaOMe, rt, overnight; e) CSA, benzaldehyde dimethyl acetal, DMF, 60 °C, overnight, 77% (2 steps); f) NH2CH2CH2NH2, EtOH, 80 °C, 2 h, 95%; g) MeOH, THF, K2CO3, Cu(II)SO4·5 H2O, 0 °C → rt, 1H-imidazole-1-sulfonyl azide hydrochloride, 5 h, 87%; h) NaH, BnBr, DMF, 0 °C → rt, 3.5 h, 91%; i) anhydrous MeOH / CH2Cl2, CSA, rt, 5 h, 92%; j) CH2Cl2, pyridine, BzCl, -50°C, 2 h, 88%; j)
[0200] (Ethyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside, intermediate I.35) [ka] Commercially available I.33 (20 g, 92.8 mmol, 1 equiv.) was dissolved in 120 mL of 1:2 v / v MeOH:H2O solution, to which NaOH pellets (4.3 g, 107.59 mmol, 1.16 equiv.) were added and stirred at rt until the pellets were completely dissolved. Phthalic anhydride (15.93 g, 107.59 mmol, 1.16 equiv., dissolved in acetone) was then added to the mixture, and after stirring for 3 h, additional phthalic anhydride (6.18 g, 41.74 mmol, 0.45 equiv.) and NaHCO3 (15.58 g, 185.5 mmol, 2 equiv.) were added. The solution was then acidified to pH 1 with 4 M HCl and the volume of the solvent was reduced by half. The mixture was allowed to stand overnight at rt, resulting in the formation of a precipitate. The reaction vessel was cooled in an ice bath for 1 hour to aid further precipitation, then filtered to collect a white solid. The solid was washed twice with cold distilled water and cold EtOH. The resulting solid was then dried under vacuum, then suspended in pyridine (200 mL) and cooled on ice. Ac2O (180 mL) was added slowly through the dropping funnel over 30 minutes, and after all addition, the reaction mixture was allowed to warm slowly back to rt and stirred overnight. The solvent was removed by repeated coevaporation with toluene, and the resulting residue was dissolved in CH2Cl2 and washed successively with 2M HCl, saturated aqueous NaHCO3, H2O, and brine. The organic layer was dried over MgSO4, filtered, concentrated, and the resulting residue was diluted with EtOH and stirred overnight to precipitate the product as a white solid. The solid was isolated by filtration, washed with cold EtOH, and dried under vacuum to give intermediate I.34 (20.8 g, 43.56 mmol, 47%) as a white solid (R f : 0.26 (cyclohexane / EtOAc, 3:2 v / v). 1 H NMR and 13C NMR is in agreement with the literature: Synlett 2008, 2008(10), 1483-1486).
[0201] Intermediate I.34 (21.5 g, 45.03 mmol, 1 equiv) was dissolved in 220 mL of anhydrous ClCH2CH2Cl and placed on ice. HSEt (8.12 mL, 112.58 mmol, 2.5 equiv) was added and the mixture was stirred for 5 min, after which TMSOTf (12.1 mL, 67.55 mmol, 1.5 equiv) was added and stirred on ice for 30 min, then warmed back to rt. After 30 min, the mixture was heated to 40° C. and after 4 h, starting material was no longer visible by TLC. The reaction mixture was cooled back to rt, placed on ice, and quenched with NEt3 (18.8 mL, 135.1 mmol, 3 equiv). The solvent was evaporated and the resulting residue was dissolved in EtOAc and washed with H2O, saturated aqueous NaHCO3, and brine. The organic layer was dried over MgSO4, filtered and concentrated to give a yellow syrup, which was purified by flash chromatography (Tol / EtOAc 5-40%) to give intermediate I.35 (18.5 g, 38.58 mmol, 86%) as a white foam (R f : 0.24 (Tol / EtOAc, 6:1 v / v) [ka] This is consistent with Carbohydr. Res. 1985, 139, 105-113.
[0202] (Ethyl 2-amino-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside, intermediate I.37) [ka] Intermediate I.35 (18.3 g, 39.32 mmol, 1 equiv) was suspended in anhydrous MeOH (180 mL), freshly prepared NaOMe was added at rt, and the mixture was stirred overnight. The reaction was then quenched by the addition of DOWEX 50WX8 acid resin until pH 7 was reached, after which the mixture was filtered and washed with MeOH. The resulting filtrate was concentrated and coevaporated once with toluene. The crude material was dried overnight and then dissolved in anhydrous DMF (140 mL). Benzaldehyde dimethyl acetal (17.7 mL, 117.96 mmol, 3 equiv) and CSA (6.39 g, 27.52 mmol, 0.7 equiv) were then added, and the mixture was heated at 60 °C and stirred overnight. The next day, the mixture was cooled to rt, placed on ice, and quenched with NEt3 (16.4 ml, 117.96 mL, 3 equiv). The solvent was removed in vacuo and the resulting residue was co-evaporated twice with cyclohexane. The resulting syrup was then purified by flash chromatography (Tol / EtOAc 5-40%) to give intermediate I.36 (13.4 g, 30.4 mmol, 77%) as a white foam (R f : 0.37(Tol / EtOAc, 4:1 v / v). 1 H NMR and 13 C NMR is in agreement with the literature European J. Org. Chem. 2009, 2009(7), 997-1008).
[0203] Intermediate I.36 (4.2 g, 9.51 mmol, 1 equiv.) was suspended in EtOH (100 mL), ethylenediamine (24 mL, 380.4 mmol, 40 equiv.) was added, and the mixture was stirred at 80° C. for 2 h, when TLC showed no more starting material. The mixture was cooled back to rt, the solvent was removed in vacuo, and the resulting yellow residue was co-evaporated twice with MeCN and once with toluene. The residue was purified by column chromatography (100 CHCl→95:5 CHCl / MeOH) to give intermediate I.37 (2.8 g, 8.99 mmol, 95%) as a white solid (R f : 0.10(EtOAc) [ka] This is consistent with the literature, Tetrahedron, 1997, 53(52), 17727-17734.
[0204] (Ethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside, intermediate I.39) [ka] Intermediate I.37 (3.53 g, 11.34 mmol, 1 equiv.) was dissolved in anhydrous THF (11 mL) and anhydrous MeOH (43 mL) and then reacted with anhydrous Cu(II) . SO4 . 5 H2O (11 mg, 0.05 mmol, 0.01 equiv), anhydrous K2CO3 (1.02 g, 7.23 mmol, 1.5 equiv), and 1H-imidazole-1-sulfonyl azide hydrochloride (1.21 g, 5.78 mmol, 1.2 equiv, prepared by the method described in Org. Lett., 2007, 9(19), 3797-3800) were added at rt under N2. The mixture was stirred for 5 h, when TLC showed no more starting material. The reaction mixture was diluted with CH2Cl2 (50 mL) and washed twice with H2O (30 mL). The organic layer was dried over MgSO4, filtered, and concentrated to give a pale yellow solid. This was purified by flash chromatography (Tol / EtOAc 3-28%) to give intermediate I.38 (3.33 g, 9.87 mmol, 87%) as a white solid (R f : 0.42(Tol / EtOAc, 6:1 v / v), 1 H NMR and 13 C NMR is consistent with the literature, Tetrahedron 1997, 53(52), 17727-17734).
[0205] Intermediate I.38 (4.2 g, 12.45 mmol, 1 equiv) was dissolved in anhydrous DMF (18.6 mL) and cooled on ice. 60% NaH in mineral oil (1.25 g, 31.13 mmol, 2.5 equiv) was added under N2 and the mixture was stirred on ice for 30 min. BnBr (3.7 mL, 31.13 mmol, 2.5 equiv) was then added slowly and after stirring on ice for 5 min the reaction was allowed to warm back to room temperature. After 3 h 40 min no more starting material was seen by TLC and the reaction was placed on ice and carefully quenched by the addition of MeOH (10.1 mL, 249 mmol, 20 equiv). The solvent was removed in vacuo and the residue was coevaporated with toluene three times. The residue was dissolved in EtOAc (150 mL) and washed twice with H2O (180 mL). The combined aqueous layers were re-extracted with additional EtOAc. The combined organic layers were dried over MgSO4, filtered, and concentrated to give a residue that was purified by flash chromatography (cyclohexane / EtOAc 3-28%) to afford I.39 (4.85 g, 11.35 mmol, 91%) as a white solid (R f : 0.31 (cyclohexane / EtOAc, 6:1 v / v) [ka] This is consistent with the literature Tetrahedron 1997, 53(52), 17727-17734.
[0206] (Ethyl 2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-thio-β-D-glucopyranoside, intermediate I.41) [ka] Intermediate I.39 (1.07 g, 2.5 mmol, 1 equiv) was dissolved in anhydrous MeOH:CH2Cl2 (24 mL, 8:1 v / v) at rt and once completely dissolved, CSA (407 mg, 1.75 mmol, 0.7 equiv) was added under N2. After 4 h 20 min, additional CSA (58 mg, 0.25 mmol, 0.1 equiv) was added at rt. After 30 min, while cooling on ice, the reaction was quenched by the addition of NEt3. The solvent was concentrated and the resulting syrup was purified by flash chromatography (cyclohexane / EtOAc 8-66%) to give intermediate I.40 (786 mg, 2.32 mmol, 92%) as a clear syrup (R f : 0.20 (cyclohexane / EtOAc, 2:1 v / v) 1 H NMR and 13 C NMR is in agreement with the literature: Angew. Chemie - Int. Ed. 2017, 56(9), 2312-2317).
[0207] Intermediate I.40 (775 mg, 2.28 mmol, 1 equiv) was dissolved in anhydrous CHCl (3.6 mL), anhydrous pyridine (0.7 mL) was added, and the mixture was cooled to −50° C. After stirring at this temperature for 5 min, BzCl (260 μL, 2.28 mmol, 1 equiv) was added under N and then stirring was continued at −50° C. After 1.5 h, an additional 50 μL (0.4 mmol, 0.18 equiv) BzCl was added, and after 20 min, the reaction was quenched by the addition of water and CHCl. The mixture was then washed successively with 2M HCl, saturated aqueous NaHCO, H0, and brine. The organic layer was dried over NaSO, filtered, and concentrated. The resulting residue was purified by flash chromatography (cyclohexane / EtOAc 8-66%) to afford I.41 (887 mg, 2.00 mmol, 88%) as a white solid (R f : 0.53 (cyclohexane / EtOAc 2:1 v / v) [ka] HR-MS calculated for C22H25N3O5NaS[M+Na]+: 466.1413 Found: 466.1396).
[0208] (vi) Synthesis of monosaccharide E with a linker [ka] Scheme 6 Reagents and conditions: Synthesis of intermediate I.43. NIS, TMSOTf, CH2Cl2, -35°C, 30 min. 86% (α / β ratio 1:4).
[0209] (N-benzyl-N-benzyloxycarbonyl-5-aminopentanol, intermediate I.42) [ka] Commercially available 5-amino-pentan-1-ol (5.31 g, 51.47 mmol, 1 equiv.) was dissolved in 80 mL of absolute EtOH and benzaldehyde (5.4 mL, 53.01 mmol, 1.1 equiv.) was added. The solvent was slowly removed on a rotary evaporator at 50° C. over 3 h. An additional 80 mL of absolute EtOH was added and the mixture was concentrated until no more solvent condensed. The residue was then coevaporated twice with toluene under reduced pressure and then dissolved in 70 mL of MeOH and cooled to 0° C. NaBH4 (2.3 g, 60.74 mmol, 1.2 equiv.) was then added slowly in small portions, allowing gas evolution to cease until the next addition. Once all the NaBH4 had been added, the reaction was allowed to warm to room temperature and stirred for 2 h. It was placed back on ice and AcOH (5.3 mL, 92.65 mmol, 1.8 equiv) was added slowly to quench the remaining NaBH4. K2CO3 (12.1 g, 87.5 mmol, 1.7 equiv) in H2O (75 mL) was added and the mixture was stirred at room temperature overnight. The next day, the mixture was diluted with 100 mL of Et2O and the layers were separated. The aqueous layer was extracted once more with Et2O. The combined organic layers were concentrated to approximately half the volume. 130 mL of saturated aqueous NaHCO3 solution was added and the biphasic mixture was cooled to 0°C. CbzCl (7.3 mL, 51.5 mmol, 1.1 equiv) was then added slowly and the mixture was allowed to warm slowly to room temperature and stirred overnight. The next day, the mixture was diluted with 200 mL of Et2O and the layers were separated. The organic layer was then washed successively with 1M HCl, H2O, and brine. After drying over MgSO4 and filtration, the filtrate was concentrated and the crude material was purified by column chromatography using 3:1→1:1 cyclohexane / ethyl acetate to give 10.64 g of intermediate I.42 as a clear syrup (32.5 mmol, 63% over three steps). [ka] (In agreement with the literature Org. Lett. 2013, 15(9), 2270-2273).
[0210] (N-Benzoxycarbonyl-N-benzyl-5-amino-pentanyl 2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-β-D-glucopyranoside, intermediate I.43-β) [ka] (N-Benzyl-N-carboxybenzyl-pentanyl 2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-α-D-glucopyranose, intermediate I.43-α) [ka] Intermediate I.41 (1.21 g, mmol, 1 eq.) and intermediate I.42 (1.79 g, mmol, 2 eq.) were coevaporated with toluene, dried under vacuum for 1 h, and then dissolved in 40 mL of anhydrous CHCl. The mixture was cooled to -40°C and the reaction vessel was wrapped in foil to protect from light. NIS (1.3 eq., dried under vacuum, protected from light) was then added, followed by TMSOTf (0.1 eq.). The reaction was stirred in the dark and gradually warmed for 45 min, when TLC (1:1 v / v pentane / EtO) showed no remaining thioglycoside. The reaction was quenched by the addition of solid KCO and 20 mL of aqueous 10% NaSO solution. The mixture was transferred to a separatory funnel and shaken until colorless. 100 mL of EtO was added and the aqueous layer was removed. The organic layer was washed with water and brine, then dried over MgSO4 and filtered. The filtrate was concentrated and the resulting crude syrup was purified using automated flash chromatography (12-100% pentane / Et2O) to first elute intermediate I.43-α (340 mg, 0.48 mmol, 17%) followed by intermediate I.43-β (1.2 g, 1.69 mmol, 69%) as a clear syrup.
[0211] Information on the β anomer; R f = 0.27 (1 / 1 v / v pentane / Et2O), HRMS C 40 H 45 N4O8[M+H] +Calculated value: 709.3237, measured value: 709.3204 [ka]
[0212] Information on the α anomer; (R f : 0.28 (1:1 v / v pentane / Et2O), [α] D +51.6(c=1, DMSO) [ka] HR-MS C 40 H 45 N4O8[M+H] + Calculated value: 709.3237 Measured value: 709.3204)
[0213] (vii) Synthesis of disaccharide building block BC [ka] Scheme 7, Reagents and Conditions: Synthesis of intermediate I.46 a) Ag2CO3, molecular sieves 4 Å, anhydrous CH2Cl2, dark, b) Ac2O, TBSOTf, 0° C., 10 min, 70%; b) Thiourea, THF / EtOH 1:1, 80° C., 3 h 75%
[0214] (Methyl 2,3-di-O-benzyl-4-O-chloroacetyl-β-D-glucopyranosyl-uronate-(1→4)-3-O-acetyl-1,6-anhydro-2-azido-2-deoxy-β-D-glucopyranose, intermediate I.44) [ka] Ag2CO3 Method: A solution of intermediate I.9 (537 mg, 1.0 mmol, 1 equiv.), intermediate I.16 (930 mg, 4.0 mmol, 4.0 equiv.), and freshly activated 4 Å molecular sieves (560 mg) in anhydrous CHCl (6 mL) was stirred in the dark under N atmosphere at rt for 30 min, after which AgCO (560 mg, 2.0 mmol, 2 equiv.) was added. The mixture was stirred for 6 days, after which TLC analysis showed complete conversion of donor to product (toluene / acetone 8:2). The reaction mixture was filtered through Celite. The filtrate was concentrated in vacuo and purified by automated flash chromatography (toluene / acetone 92 / 8 to 75 / 25) to give intermediate I.44 (343 mg, 0.5 mmol, 50% only for the β anomer) as a white solid.
[0215] Ag2CO3 / AgOTf method: Donor 1.9 (444 mg, 0.84 mmol, 1.5 equiv) and acceptor I.16 (130 mg, 0.56 mmol, 1.0 equiv) were dried overnight on a Schlenck line. 4 Å molecular sieves and anhydrous CHCl (10 mL) were added and the mixture was stirred at rt in the dark under N for 1 h. AgCO (309 mg, 1.12 mmol, 2 equiv) and AgOTf (144 mg, 0.56 mmol, 1 equiv) were added and the reaction was stirred for 30 min (TLC cyclohexane / ethyl acetate 1:1). The reaction was quenched with TEA and filtered through Celite. The filtrate was concentrated in vacuo and purified by flash chromatography with cyclohexane / ethyl acetate 6:4 to give intermediate I.44 (178 mg, 0.26 mmol, 47% only for the β anomer) as a white solid (R f (toluene / acetone 1:1) 0.33. [ka] HR-MS: C 31 H 35 ClNO 12 Na[M+Na + ]Calculated value: 699.1807, measured value: 699.1807).
[0216] (Methyl 2,3-di-O-benzyl-4-O-chloroacetyl-β-D-glucopyranosyl-uronate-(1→4)-1,3,6-tri-O-acetyl-2-azido-2-deoxy-D-glucopyranose, intermediate I.45) [ka] A solution of intermediate I.44 (324 mg, 0.48 mmol, 1 equiv) in acetic anhydride (5 mL, 0.1 M) was cooled to 0 °C and TBSOTf (10 μL, 0.048 mmol, 0.1 equiv) was added. After 15 min, TLC (cyclohexane / ethyl acetate 4:6) showed the formation of the product. The reaction was quenched with TEA and the solvent was evaporated under vacuum. The crude was purified by chromatography (cyclohexane / ethyl acetate 80 / 20 to 40 / 60) to give I.45 as a white foam (272 mg, 0.35 mmol, 73%) in an α / β mixture 80 / 20 (R f (cyclohexane / ethyl acetate 4:6) 0.65 [ka] HR-MS: C 35 H 40 ClNO 15 Na[M+Na + ] calculated value: 800.2046, measured value: 800.2023).
[0217] (Methyl 2,3-di-O-benzyl-β-D-glucopyranosyl-uronate-(1→4)-2-azido-1,3,6-tri-O-acetyl-2-deoxy-α / β-D-glucopyranose, intermediate I.46) [ka] To a solution of intermediate I.45 (195 mg, 0.25 mmol, 1 equiv.) in THF / EtOH 1:1 (2.5 mL, 0.1 M) was added thiourea (75 mg, 1.0 mmol, 4 equiv.). The reaction was stirred at 80° C. for 3 h, after which TLC (cyclohexane / ethyl acetate 1:1) showed complete conversion of starting material to product. The reaction was evaporated and the crude was dissolved in CHCl and washed with water. The organic phase was dried over MgSO, filtered and evaporated. The crude was purified by chromatography (cyclohexane / ethyl acetate 7:3→6:4) to give intermediate I.46 as a white solid (140 mg, 0.20 mmol, 80%) in an α / β mixture 80 / 20 (R f :(cyclohexane / ethyl acetate 1:1) 0.43. [ka] HR-MS: C 33 H 39 N3O 14 Na[M+Na + ] calculated value: 724.2330, measured value 724.2307).
[0218] (viii) Synthesis of disaccharide building block DE [ka] Scheme 8, Reagents and Conditions: Synthesis of I.49 a) NIS, AgOTf, CH2Cl2, -40 °C, 80 min; b) HSEt, p-TsOH·H2O, CH2Cl2, 70% over two steps; c) TEMPO / BAIB, CH2Cl2 / H2O 2:1 v / v, rt, 6 h; d) TMSCHN2, Tol / MeOH (1:1 v / v), 0 °C, 20 min, 50% over two steps.
[0219] (N-Benzyl-N-carboxybenzyl-5-aminopentanyl 2-O-benzoyl-3-O-benzyl-4-α-L-idopyranosyl-(1→4)-2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-β-D-glucopyranoside intermediate I.48) [ka] Intermediate I.32 (650 mg, 0.92 mmol, 1 equiv.) was coevaporated with toluene in the presence of intermediate I.43-β (650 mg, 1.17 mmol, 1.3 equiv.) and dried under vacuum with a stir bar and 1.02 g of 4 Å MS for 2 h, after which anhydrous CHCl was added. The mixture was stirred at room temperature for 45 min and then cooled to −40° C. Then NIS (290 mg, 1.29 mmol, 1.4 equiv.), previously dried under vacuum protected from light, was added, followed by a catalytic amount of AgOTf (dried under vacuum protected from light before use). The reaction was stirred and TLC showed that the donor was no longer present and a new spot was present in R f = 0.7 (Tol / EtOAc, 8 / 2 v / v). The reaction was quenched by the addition of NEt3, the mixture was filtered through a pad of Celite and diluted until the filtrate was clear. The solvent was removed under concentration and the remaining crude was purified by column chromatography (2-20% Tol / EtOAc) and the product-containing fractions were combined and concentrated to give intermediate I.47 as a white foam.
[0220] The crude disaccharide I.47 (900 mg, 0.78 mmol, 1 equiv) was dried under vacuum in the presence of p-TsOH·HO (22 mg, 0.1 equiv) and then dissolved in 5 mL of anhydrous CHCl. HSEt (0.6 mL, 7.8 mmol, 10 equiv) was then added at room temperature and the reaction was stirred until TLC (3 / 2 v / v cyclohexane / ethyl acetate) showed significant conversion to the lower spot. The reaction was placed on ice and quenched by the addition of NEt. The solvent was removed and the crude syrup was purified by column chromatography (cyclohexane / EtOAc 7 / 3→6 / 4) to give intermediate I.48 (701 mg, 0.66 mmol, 72% for two steps) as a white foam (R f =0.35 (3 / 2 v / v cyclohexane / EtOAc) HRMS C 60 H 64 N4O 14 Na[M+Na] +Calculated value: 1087.4317 Measured value: 1087.4357 [ka]
[0221] (N-Benzyl-N-benzyloxycarbonyl-pentanyl(methyl(2-O-benzoyl-3-O-benzyl-α-L-idopyranosyl)uronate)-(1→4)-2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-β-D-glucopyranoside, intermediate I.49) [ka] Intermediate I.48 (340 mg, 0.19 mmol, 1 equiv) was dissolved in CH2Cl2 / H2O (3 mL, 2:1 v / v) with vigorous stirring. TEMPO (10 mg, 0.06 mmol, 0.2 equiv) was then added followed by BAIB (258 mg, 0.8 mmol, 2.5 equiv). The reaction was stirred for 6 h before being quenched with 10 mL of aqueous 10% Na2S2O3 solution and stirred for an additional 15 min. The mixture was diluted with CH2Cl2 and transferred to a separatory funnel. The organic layer was set aside and the aqueous layer was acidified with 1 M HCl. The aqueous layer was extracted three more times with CH2Cl2. The combined organic layers were dried over MgSO4, filtered and concentrated. The crude residue was purified to isolate the carboxylic acid with 2:1 cyclohexane / ethyl acetate → 2:1 cyclohexane / ethyl acetate + 1% AcOH → 1:1 cyclohexane / ethyl acetate + 1% AcOH. The fractions containing the carboxylic acid were combined, concentrated, and the residue was coevaporated twice with toluene to remove remaining traces of acid, then dried under vacuum for 2 h to give the intermediate acid (190 mg, 0.17 mmol).
[0222] The residue was dissolved in 1 mL of anhydrous MeOH / anhydrous toluene (1:1 v / v) and cooled on ice. TMSCHN2 (2M in Et2O, 0.1 mL, 0.19 mmol, 1.1 equiv) was then added dropwise. The reaction was stirred for 20 min, after which AcOH was added dropwise until no more gas was evolved and the solution was light in color. The reaction was diluted with additional toluene, the solvent was removed in vacuo, and the crude was coevaporated with toluene three more times. The crude was purified using column chromatography (3:1→2:1 cyclohexane / ethyl acetate) to give intermediate I.49 as a white foam (180 mg, 0.16 mmol, 50% over two steps) (R f =0.28 (2 / 1 v / v cyclohexane / EtOAc) HRMS: C 61 H 64 N4O 15 Na[M+Na] + Calculated value: 1115.4266. Measured value: 1115.4231 [ka]
[0223] (ix) Synthesis of trisaccharide building block ABC [ka] Scheme 9. Reagents and conditions: synthesis of intermediate I.52 a) TBSOTf, anhydrous toluene, 4 Å ms; -20°C, 1.5 h, 85%; b) EDA, AcOH, THF, 40°C, overnight, 70%; c) Cl3CCN, K2CO3, anhydrous CH2Cl2, overnight, rt, quantitative
[0224] (6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl-(1→4)-O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1→4)-2-azido-1,3,6-triacetyl-2-deoxy-α / β-D-glucopyranose, intermediate I.50) [ka] A mixture of trichloroacetimidate I.20 (230 mg, 0.40 mmol, 1.5 equiv), intermediate I.46 (190 mg, 0.27 mmol, 1 equiv), and freshly activated 4 Å molecular sieves (125 mg) in anhydrous toluene (4 mL) was stirred at room temperature for 30 min under N2 atmosphere. The solution was cooled to -20 °C and TBSOTf (31 μL, 0.135 mmol, 0.5 equiv) was added dropwise. The resulting solution was stirred for 1 h 30 min to achieve room temperature, after which TEA was added to quench the reaction. The entire mixture was filtered through Celite and evaporated in vacuum. The crude was purified by automated flash chromatography (cyclohehane / ethyl acetate 80 / 20 to 60 / 40) to give the trisaccharide I.50 (257 mg, 0.23 mmol, 85%) as a white foam (R f (cyclohexane / ethyl acetate 7:3) 0.55 [ka] HR-MS: C 55 H 62 NO 19 Na[M+Na + ] calculated value: 1133.3967, measured value: 1133.3967).
[0225] (6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl-(1→4)-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1→4)-2-azido-3,6-diacetyl-2-deoxy-α / β-D-glucopyranose, intermediate I.51) [ka] Trisaccharide I.50 (108 mg, 0.097 mmol, 1 equiv.) was dissolved in THF (0.1 M) and ethylediamine (7.7 μl, 0.116 mmol, 1.2 equiv.) and acetic acid (6.6 μl, 0.116 mmol, 1.2 equiv.) were added. The reaction was stirred at 40° C. overnight, after which it was diluted with CHCl and washed with 1 M HCl. The aqueous phase was extracted twice with CHCl. The combined organic layers were washed with aqueous saturated NaHCO and brine, dried over MgSO and evaporated. The crude was purified by automated chromatography (cyclohexane / ethyl acetate 80 / 20→40 / 60) to give intermediate I.51 (73 mg, 0.068 mmol, 70%) in the α / β mixture as a white foam (R f (cyclohexane / ethyl acetate 6:4) 0.34 [ka]
[0226] (6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl-(1→4)-methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate-(1→4)-3,6-di-O-acetyl-2-azido-2-deoxy-α / β-D-glucopyranosyltrichloroacetimidate, intermediate I.52) [ka] Trichloroacetonitrile (0.460 mL, 1.6 mmol, 10 equiv.) was added to a solution of intermediate 1.51 (170 mg, 0.16 mmol, 1 equiv.) and K2CO3 (110 mg, 0.80 mmol, 5 equiv.) in anhydrous CHCl2 (8 mL, 0.1 M) under N2 atmosphere. The mixture was stirred at room temperature overnight, then filtered through a pad of Celite and evaporated in vacuum. The product intermediate 1.52 obtained as an α / β mixture was used directly in the next glycosylation step without further purification (TLC analysis cyclohexane / ethyl acetate 6:4 ESI-MS: C 55 H 60 Cl3NO 18[M] calculated value: 1211.31, measured value: 1235.58).
[0227] (x) Synthesis of protected pentasaccharide with linker [ka] Scheme 10. Reagents and Conditions: Synthesis of Intermediate I.53 a) 0.1 M TfOH in anhydrous toluene, molecular sieves 4 Å, anhydrous toluene, −40° C.;
[0228] (N-(benzyl)-benzyloxycarbonyl-5-aminopentyl 6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl-(1→4)-methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate-(1→4)-3,6-di-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl-(1→4)-methyl 2-O-benzoyl-3-O-benzyl-α-L-idopyranosyluronate-(1→4)-2-azido-6-O-benzoyl-3-benzyl-2-deoxy-β-D-glucopyranoside, intermediate I.53) [ka] A mixture of intermediate I.52 (85 mg, 0.07 mmol, 1.5 equiv), intermediate I.49 (50 mg, 0.046 mmol, 1 equiv), and freshly activated 4 Å molecular sieves (65 mg) in anhydrous toluene (2 mL) was stirred at room temperature for 30 min under N2 atmosphere. The solution was cooled to -40 °C and 0.1 M TfOH in anhydrous toluene (0.230 mL, 0.023 mmol, 0.5 equiv) was added dropwise. The resulting solution was stirred for 1 h, during which time the temperature rose to 5 °C and TEA was added to quench the reaction. The entire mixture was filtered through Celite and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (toluene / acetone 98 / 2 to 96 / 4) to give intermediate I.53 (45 mg, 0.02 mmol, 56%) as a white solid (R f (Toluene / Acetone 9:1) 0.51 [ka]
[0229] (xi) Synthesis of pentasaccharide with linker [ka] Scheme 11. Reagents and conditions: synthesis of example 1.1 a) 5M NaOH in H2O, CH3OH, CH2Cl2, rt, 80%; b) SO3·NMe3, DMF, MW 100 °C, c) i. 1M PMe3 in THF, 1M NaOH in H2O, THF, rt; ii. SO3·Py, Py, TEA, rt; d) H2, Pd / C, Pd(OH)2, EtOH / H2O.
[0230] (N-(benzyl)-benzyloxycarbonyl-5-aminopentyl 2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl-(1→4)-2,3-di-O-benzyl-β-D-glucopyranosyluronic acid-(1→4)-2-azido-2-deoxy-α-D-glucopyranosyl-(1→4)-3-O-benzyl-α-L-idopyranosyluronic acid-(1→4)-2-azido-3-benzyl-2-deoxy-β-D-glucopyranoside, intermediate I.54) [ka] Intermediate I.53 (32 mg, 0.015 mmol, 1 equiv) was dissolved in a mixture of methanol / dichloromethane (1 mL / 0.73 mL) and 0.35 mL of 5M NaOH in H2O was added dropwise. The reaction was stirred at room temperature overnight, then diluted with CHCl2 and washed with 1M HCl. The aqueous phase was extracted twice with CHCl2. The combined organic phases were dried over MgSO4 and evaporated in vacuo. The crude was dissolved in CHCl2 / CH3OH 1:1 and layered on top of Sephadex LH-20, which was eluted with the same eluent mixture. Fractions were collected every 3 min by an automatic collector. The fractions containing the product were evaporated under vacuum to give intermediate I.54 as a white solid (22.5 mg, 0.012 mmol, 80%) (Rf (Dichloromethane / methanol 9:1) 0.40 [ka] ESI-MS: C 92 H 102 N 10 O 27 2- [M] calculated value: 1778.69, measured value: 1778.44).
[0231] (N-(benzyl)-benzyloxycarbonyl-5-aminopentyl 2-azido-3,4-di-O-benzyl-2-deoxy-6-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3-di-O-benzyl-β-D-glucopyranosyluronic acid-(1→4)-2-azido-2-deoxy-3,6-di-O-sulfo-α-D-glucopyranosyl-(1→4)-3-O-benzyl-2-O-sulfo-α-L-idopyranosyluronic acid-(1→4)-2-azido-3-benzyl-2-deoxy-6-O-sulfo-β-D-glucopyranoside, intermediate I.55) [ka] Intermediate I.54 (19 mg, 0.01 mmol, 1 equiv.) was dissolved in anhydrous DMF (1 mL) and placed in a microwave vial along with previously Schlenck-dried SO3·NMe3 (42 mg, 0.30 mmol, 30 equiv.). The reaction was carried out in a microwave reactor at 100 °C for 2 h. The reaction was then quenched with TEA, filtered through a 22 μm pore filter, and layered onto Sephadex LH-20, which was eluted with CHCl / CHOH (1:1) to give the triethylamine salt of intermediate I.55 as a slightly yellow solid (25 mg) (R f (Dichloromethane / methanol / ammonium hydroxide (7:3:1) 0.34) [ka]
[0232] (N-(benzyl)-benzyloxycarbonyl-5-aminopentyl 3,4-di-O-benzyl-2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3-di-O-benzyl-β-D-glucopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-3,6-di-O-sulfo-α-D-glucopyranosyl-(1→4)-3-O-benzyl-2-O-sulfo-α-L-idopyranosyluronic acid-(1→4)-3-benzyl-2-deoxy-2-sulfamido-6-O-sulfo-β-D-glucopyranoside, intermediate I.56) [ka] Intermediate I.55 (21 mg, 0.01 mmol, 1 equiv.) was dissolved in THF (0.5 mL) and treated with 1 M NaOH in HO (0.24 mL, 0.24 mmol, 24 equiv.). 1 M PMe3 in THF (0.30 mL, 0.30 mmol, 30 equiv.) was added and the reaction was stirred at room temperature overnight. The reaction was quenched with 1 M HCl and evaporated. The crude was dissolved in a 1:1 mixture of CH2Cl2 / CH3OH and layered on top of Sephadex LH-20, which was eluted with the same eluent mixture. The fractions containing the product were evaporated under vacuum. The resulting amino derivative was dissolved in anhydrous pyridine and TEA and SO3·Py (43 mg, 0.27 mmol, 30 equiv.) was added in four portions. The reaction was left stirring overnight, after which it was diluted with a 1:1 mixture of CH2Cl2 / CH3OH and layered onto Sephadex LH-20, which was eluted with the same eluent mixture to give intermediate I.56 as the triethylamine salt (24 mg) (R f (Dichloromethane / methanol / ammonium hydroxide 7:3:1.2) 0.31)
[0233] (5-Aminopentyl 2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl-(1→4)-β-D-glucopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-3,6-di-O-sulfo-α-D-glucopyranosyl-(1→4)-2-O-sulfo-α-L-idopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-6-O-sulfo-β-D-glucopyranoside (Example 1.1)) [ka] Intermediate I.56 (29 mg, 0.012 mmol, 1 equiv.) dissolved in EtOH / H2O 1:1 (1 mL) was hydrogenated in the presence of Pd / C (30 mg) and Pd(OH)2 (30 mg). The reaction was carried out in a hydrogenator reactor at 25 bar pressure for 48 h. The suspension was filtered through a 22 μm pore filter and concentrated. The crude was dissolved in water and added to DOWEX Na + After stirring with for 1 h and filtration, the solvent was evaporated. The crude was purified by reverse phase (HO / ACN 9:1). After freeze-drying, Example 1.1 was obtained as a white solid (14 mg, 0.009 mmol, 75%) (R f (Ethyl acetate / methanol / water 4:3:3) 0.32 [ka]
[0234] (Example 1.2, 5-aminopentyl 2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl-(1→4)-β-D-glucopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-3,6-di-O-sulfo-α-D-glucopyranosyl-(1→4)-2-O-sulfo-α-L-idopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranoside) [ka] Example 1.2 was obtained utilizing the same synthetic route as for the preparation of Example 1.1, but substituting I.43-α for I.43-β. [ka]
[0235] (Example 1.3: Methyl 4-O-(5'-aminopentanyl)-2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl-(1→4)-β-D-glucopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-3,6-di-O-sulfo-α-D-glucopyranosyl-(1→4)-2-O-sulfo-α-L-idopyranosyluronic acid-(1→4)-2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranoside) [ka] The synthetic route for this molecule is outlined in FIG.
[0236] (i) Synthesis of building blocks having a linker at the non-reducing end [ka] Scheme 12. Reagents and Conditions: Synthesis of Intermediate I.61 a) TiCl4, CH2Cl2, 0 °C, 45 min. 75%. b) NaH, (28), DMF, 0 °C~rt, overnight, 68%; c) TBSOTf, Ac2O, 0 °C, 20 min, 78%. d) DMAPA, THF, rt, 3 h, 78%; e) K2CO3, Trichloracetonitrile, CH2Cl2, rt.
[0237] (1,6-anhydro-2-azido-3-O-benzyl-2-deoxy-β-D-glucopyranose, intermediate I.57) [ka] Intermediate I.17 (1.22 g, 3.32 mmol, 1 equiv.) was dissolved in 45 mL of anhydrous CHCl and placed on ice. TiCl (360 μL, 3.32 mmol, 1 equiv.) was then added slowly. The reaction was stirred on ice for 45 min, and TLC (cyclohexane / EtOAc 2:1 v / v) showed disappearance of starting material. The reaction was quenched by pouring it into a mixture of ice water and stirring it for 15 min. The layers were separated and the aqueous layer was extracted with CHCl. The combined organic layers were dried over MgSO, filtered, concentrated, and the resulting syrup was purified using (cyclohexane / EtOAc 8-66%) to give intermediate I.57 as a slightly yellow syrup 720 mg (2.6 mmol, 78%). [ka] (In agreement with the literature, J. Org. Chem. 1989, 54(6), 1346-1353).
[0238] (N-Benzyl-N-benzyloxycarbonyl-5-bromo-aminopentane, intermediate I.58) [ka] Intermediate I.42 (580 mg, 1.77 mmol, 1 equiv) was dissolved in 18 mL of anhydrous CHCl, the reaction flask was covered with aluminum foil to protect from light, and then cooled on ice. NBS (470 mg, 2.66 mmol, 1.5 equiv) and PPh (700 mg, 8.07 mmol, 1.5 equiv) were then added in one portion and the reaction was stirred for 1 h, at which time TLC (9:1 v / v cyclohexane / EtOAc) showed complete conversion of the starting material. The mixture was concentrated while protected from light, and the crude material was then purified by column chromatography using 9:1→7:3 cyclohexane / EtOAc to give intermediate I.43 as a slightly yellow syrup 600 mg (1.54 mmol, 87%). [ka] This is consistent with the literature J. ACS Cent. Sci. 2017, 3(3), 224-231.
[0239] (1,6-anhydro-4-O-(5'-N-benzyl-N'-carboxybenzyl-pentanyl)-2-azido-3-O-benzyl-2-deoxy-β-D-glucopyranose, intermediate I.59) [ka] Intermediate I.57 (147 mg, 0.53 mmol, 1 equiv) was dissolved in 2 mL of anhydrous DMF and cooled on ice before adding NaH (60% in mineral oil, 53 mg, 1.33 mmol, 2.5 equiv). After stirring for 45 min, the flask was covered with aluminum foil to block light and a solution containing bromide linker I.58 (320 mg, 0.82 mmol, 1.5 equiv) dissolved in 2 mL of anhydrous DMF was added dropwise to the mixture. The reaction was allowed to warm to room temperature and stirred overnight. The next day, the reaction was cooled on ice and quenched with H2O. The mixture was extracted twice with CHCl2 and the combined organic phases were dried over MgSO4, filtered and concentrated. The resulting crude material was purified using flash chromatography (cyclohexanecyclohexane / EtOAc 8-50%) to give intermediate I.59 as a clear oil (210 mg, 0.36 mmol, 68%) (R f =0.2 (cyclohexane / EtOAc, 4 / 1 v / v) HRMS: C 33 H 38 Calculated value of N4O6Na: 609.2689 [M+Na] + ;Measured value: 609.2678 [ka]
[0240] (1,6-di-O-acetyl-4-O-(5'-N-benzyl-N'-carboxybenzyl-pentanyl)-2-azido-3-O-benzyl-2-deoxy-α / β-D-glucopyranose, intermediate I.60) [ka] Intermediate I.59 (180 mg, 0.31 mmol, 1 equiv) was dissolved in Ac2O (3 mL) and placed on ice. TBSOTf (7.1 μL, 0.03 mmol, 0.1 equiv) was then added and the reaction was stirred for 15 min before being quenched with 0.1 mL of NEt3 followed by slow addition of MeOH (4 mL). The mixture was stirred on ice for 15 min before being diluted with toluene and the solvent evaporated. The crude was co-evaporated with toluene three more times before being loaded onto a column and purified with 5:1→2:1 cyclohexane / EtOAc to give intermediate I.60 as a clear oil (177 mg, 0.26 mmol, 83%, inseparable mixture of anomers, α / β 2:1 (R f =0.4 (cyclohexane / EtOAc, 3 / 1 v / v) HRMS: C 37 H 44 Calculated value for N4O9Na: 711.3006[M+Na] + ; Found: 711.3023 Selected α anomer peak: [ka]
[0241] (6-O-acetyl-4-O-(5'-N-benzyl-N'-carboxybenzyl-pentanyl)-2-azido-3-O-benzyl-2-deoxy-α / β-D-glucopyranose, intermediate I.61) [ka] Intermediate I.60 (750 mg, 1.09 mmol, 1 equiv) was dissolved in 11 mL of anhydrous THF and DMAPA (0.7 mL, 5.45 mmol, 5 equiv) was added at room temperature. The reaction was stirred until TLC analysis showed no remaining SM. The reaction was diluted with CHCl and washed with 1M HCl. The aqueous layer was re-extracted with CHCl and the combined organic layers were dried over MgSO, filtered and concentrated. The crude was purified using 3:1→2:1 cyclohexane / EtOAc to give Intermediate I.61 as a clear oil (568 mg, 0.88 mmol, 81%, inseparable mixture of anomers) (R f =0.19 (cyclohexane / EtOAc 2 / 1 v / v) HRMS: C 35 H 42 Calculated value for N4O8Na: 669.2900[M+Na] + ; Measured value: 669.2911 [ka]
[0242] (6-O-acetyl-4-O-(5'-N-benzyl-N'-carboxybenzyl-pentanyl)-2-azido-3-O-benzyl-2-deoxy-α / β-D-glucopyranose, intermediate I.62) [ka] Intermediate I.61 (135 mg, 0.21 mmol, 1 equiv.) was dried under vacuum in the presence of K2CO3 (160 mg, 1.16 mmol, 5.5 equiv.) for 2 h, after which 2 mL of anhydrous CHCl2 was added. Trichloroacetonitrile (0.2 mL, 1.99 mmol, 10 equiv.) was added at room temperature and the reaction was left stirring overnight under N2. The next day, the mixture was passed through a pad of Celite, the filtrate was concentrated (rotovap water bath temperature <25 °C) and the crude intermediate I.62 was used immediately without further analysis.
[0243] (ii) Synthesis of a trisaccharide intermediate having a linker at the non-reducing end [ka] Scheme 13 Reagents and conditions: Synthesis of intermediate I.64 b) TBSOTf, toluene, -25°C, 1.5 hours
[0244] (6-O-acetyl-4-O-(5'N-benzyl-5'N-carboxybenzyl-pentanyl)-2-azido-3-O-benzyl-2-deoxy-α-D-glucopyranosyl-(1→4)-methyl-2,3-di-O-benzyl-β-D-glucopyranosyluronate-(1→4)-1,6-anhydro-2-azido-3-O-acetyl-2-deoxy-β-D-glucopyranose, intermediate I.64) [ka] The crude TCA intermediate (I.62, 1.5 equiv.) and the commercially available disaccharide I.63 (100 mg, 0.14 mmol, 1 equiv.) were dried together under vacuum in the presence of 340 mg of 4 Å MS for 6 h, after which 5 mL of anhydrous toluene was added. The mixture was stirred at room temperature for 45 min and then cooled to −25° C. Then TBSOTf (18.4 μL, 0.07 mmol, 0.5 equiv.) was added and the reaction was stirred and warmed slowly until the donor was no longer visible by TLC. The reaction was quenched by the addition of NEt3 and the mixture was passed through a pad of Celite. The pad was washed with CHCl until the filtrate was clear, after which it was concentrated. The crude residue was purified using 7 / 3→6 / 4 cyclohexane / EtOAc to give intermediate I.64 as a yellow foam. The product co-eluted as a trisaccharide (R f =0.29 (3 / 2 v / v cyclohexane / EtOAc) HRMS: C 64 H 73 N7O 18 Calculated Na: 1250.4910. Found: 1250.4895. Selected main product peak: [ka]
[0245] [ka] Scheme 14 Reagents and Conditions: Synthesis of intermediate I.67 a) TBSOTf, Ac2O, 0°C, 30 min, 76%. b) DMAPA, THF, rt. 71%, c) K2CO3, Trichloracetonitrile, CH2Cl2, rt. overnight, d) 0.1M TfOH in anhydrous toluene, molecular sieves, 4 Å, anhydrous toluene, -40°C. Slowly warm to room temperature.
[0246] (6-O-acetyl-2-azido-3-O-benzyl-4-O-(5'-benzyl-5'-benzyloxycarbonyl-aminopentanyl)-2-deoxy-α-D-glucopyranosyl-(1→4)-O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1→4)-3,6-di-O-acetyl-2-azido-2-deoxy-α / β-D-glucopyranolactol intermediate I.65) [ka] Intermediate I.64 (175 mg, 0.14 mmol, 1 equiv) was dissolved in Ac2O (1.5 mL) and placed on ice. TBSOTf (4.6 μL, 0.01 mmol, 0.1 equiv) was then added. The reaction was stirred for 30 min and TLC (cHex / EtOAc 3 / 2 v / v) showed no starting material remaining. Then 0.2 mL of NEt3 was added followed by MeOH. The mixture was diluted with toluene and the solvent was removed in vacuo. The crude was coevaporated twice with additional toluene. The resulting crude syrup was purified by column chromatography (cHex / EtOAc 7:3→3:2 v / v) to give 6-O-acetyl-2-azido-3-O-benzyl-4-O-(5'-benzyl-5'-benzyloxycarbonyl-aminopentanyl)-2-deoxy-α-D-glucopyranosyl-(1→4)-O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1→4)-1,3,6-tri-O-acetyl-2-azido-2-deoxy-α / β-D-glucopyranose as a white foam (143 mg, 0.11 mmol, 76%, mixture of anomers). f =0.64(3 / 2 cHex / EtOAc v / v) HRMS C 68 H 79 N7NaO 21 Calculated value: 1352.5227[M+Na]+. Found value: 1352.5277 [ka]
[0247] The isolated intermediate (121 mg, 0.10 mmol, 1 equiv) was dissolved in 1 mL of anhydrous THF. Then DMAPA (38 μL, 0.3 mmol, 3 equiv) was added at room temperature. The reaction was stirred until TLC showed that no starting material (cHex / EtOAc 3 / 2 v / v) remained. The reaction was diluted with CH2Cl2 and washed with 1M HCl. The aqueous layer was extracted again with CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and the filtrate was concentrated. The crude syrup was then purified by column chromatography (cHex / EtOAc, 7:3→3:2 v / v) to give 6-O-acetyl-2-azido-3-O-benzyl-4-O-(5'-benzyl-5'-benzyloxycarbonyl-aminopentanyl)-2-deoxy-α-D-glucopyranosyl-(1→4)-O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1→4)-3,6-di-O-acetyl-2-azido-2-deoxy-α / β-D-glucopyranolactol as a white foam (91 mg, 0.07 mmol, 71%). Rf=0.29(2 / 1 cHex / EtOAc v / v) HRMS C 66 H 77 N7NaO 20 Calculated value: 1310.5121 [M+Na+]. Found value: 1310.5137
[0248] The crude material (110 mg, 0.085 mmol, 1 equiv) was dried over K2CO3 (118 mg, 0.85 mmol, 10 equiv) for 3 h, followed by the addition of 1 mL of anhydrous CHCl2. Then, trichloroacetonitrile (90 μL, 0.85 mmol, 10 equiv) was added, and the reaction was stirred at room temperature overnight. The next day, the mixture was filtered through a pad of Celite. The filtrate was concentrated on a rotary evaporator (water bath temperature <25 °C) to isolate the crude intermediate material I.65. R f =0.68(3 / 2 cHex / EtOAc+1%NEt3v / v / v) HRMS Calculated for C68H77Cl3N8Na20: 1453.4217 [M+Na+] Found: 1453.4269 [ka]
[0249] (Methyl 6-O-acetyl-2-azido-3-O-benzyl-4-O-(5'-benzyl-5'-benzyloxycarbonyl-aminopentanyl)-2-deoxy-α-D-glucopyranosyl-(1→4)-O-(methyl 2,3-di-O-benzyl-β-D-glucopyranosyluronate)-(1→4)-3,6-di-O-acetyl-2-azido-2-deoxy-α-glucopyranosyl-(1→4)-(methyl 2-O-benzoyl-3-O-benzyl-α-L-idopyranosyluronate)-(1→4)-2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-α-D-glucopyranoside, intermediate I.67) [ka] Intermediate I.65 (100 mg, 0.075 mmol, 1.5 equiv.) was dried in the presence of commercially available I.66 (40 mg, 0.05 mmol, 1 equiv.) and 90 mg of 4 Å MS. Anhydrous toluene was then added and the mixture was stirred at room temperature for 1 h. The mixture was then cooled to −40° C. TBSOTf (0.1 M in anhydrous toluene) was then added slowly. The reaction was stirred slowly and allowed to warm to room temperature. TLC showed no donor remaining and the reaction was quenched by the addition of NEt3. The mixture was passed through a pad of Celite and washed with CHCl. The solvent was removed and the crude was dissolved in CHCl and washed with 1 M HCl, saturated aqueous NaHCO3, and brine. The organic layer was dried over MgSO, filtered, and the filtrate was concentrated. The crude syrup was purified using column chromatography (Tol / Ace 100 / 0→85 / 15 v / v) to give intermediate I.67 (11 mg, 0.005 mmol, 10%). Rf 0.35(9 / 1 Tol / Ace v / v) [α] D +47.5(c=1, CHCl3) [ka] MALDI TOF C 108 H 118 N 10 NaO 32 Calculated value: 2089.7806. [M+Na]+ Found value: 2089.7584
[0250] Intermediate I.67 was then converted to Example 1.3 using the deprotection, reduction, and sulfation steps shown in Scheme 11.
[0251] Example 2: Preparation of heparin fragment fraction by depolymerization of heparin (Examples 2.1-2.3: Heparin Fragment Fractions Prepared by Depolymerization of Heparin and Subsequent Fractionation) Oligosaccharides mainly octasaccharide units in size were prepared by partial nitrous acid cleavage of native heparin and subsequent fractionation by gel chromatography. The octasaccharide produced by nitrous acid cleavage is the shortest fragment capable of containing a functionally active sequence (Thunberg L. et al., FEBS Letters 117 (1980), 203-206).
[0252] Depolymerization of heparin: 10 g of sodium heparin was dissolved in 36 ml of water by stirring overnight. 0.30 g of NaNO2 was added to the heparin solution and allowed to dissolve. The solution was acidified to pH 2.5 by addition of 4 M HCl. After a total reaction time of 2 h at room temperature, the solution was neutralized by addition of 4 M NaOH.
[0253] The digestion mixture was separated on the basis of molecular size by gel permeation chromatography (GPC), where 3 ml portions were applied to a column (HiLoad 26 / 600 Superdex 30 pg, mobile phase 0.15 M NaCl) at a flow rate of 2.5 ml / min. The collected fractions (3 ml) were analyzed for aldehydes by the MBTH reaction essentially as described by Smith RL and Gilkerson E (1979), Anal Biochem 98, 478-480. A broad peak centered at the elution position of the octasaccharide was collected. The combined oligosaccharide elution fractions from several preliminary runs were concentrated by evaporation to a volume of 18 ml and rechromatographed on the same column. For all rechromatographic runs, three fractions corresponding to the decasaccharide (2.3), octasaccharide (2.2), and hexasaccharide fragments (2.1) were collected and pooled.
[0254] The collected fractions 2.1 to 2.3 were analyzed by evaluation method A (see Figure 7). The "hexa" fraction consists of a major peak corresponding to a hexasaccharide and a shoulder corresponding to an octasaccharide. The "octa" fraction consists of a major peak corresponding to an octasaccharide with a shoulder corresponding to a hexasaccharide and a minor peak corresponding to a decasaccharide. The "deca" fraction consists of a major peak corresponding to a decasaccharide with a shoulder corresponding to an octasaccharide and a minor shoulder corresponding to a dodecasaccharide.
[0255] The concentrations of the heparin fragment fractions (see Table 2) were determined by evaluation method B. [Table 2] Table 2 Analysis of the concentration of oligosaccharide fractions
[0256] Example 3: Determination of anti-FXa activity of heparin fragment fractions in solution Anti-FXa activity was determined for Examples 1.2(α), 1.1(β), 2.1, 2.2, and 2.3 by Assessment Method C (see Table 3). All heparin fragments tested were in solution and not immobilized on a surface. [Table 3] Table 3. Anti-FXa activity of heparin fragments. In comparison, the anti-FXa activity of heparin API (sodium heparin active pharmaceutical ingredient) is ~200 IU / mg (according to the USP, Ph. Eur.).
[0257] As expected, depolymerization of heparin (which has an anti-FXa activity of about 200 IU / mg) to oligosaccharides significantly reduced the anti-FXa activity. Since the octasaccharide is the smallest fragment derived from heparin by nitrous acid that can contain a functionally active sequence (Thunberg L. et al., FEBS Letters 117 (1980), 203-206), the anti-FXa activity of the hexasaccharide fraction is probably due to the presence of several larger fragments (octasaccharides) in the fraction. The synthesized pentasaccharide compounds had higher anti-FXa activity than native heparin. This is likely due to the high proportion of active sequences present in these compounds.
[0258] Example 4: Anti-FXa activity; effect of Example 2.2 (octasaccharide fraction) in solution The anti-FXa activity of the octasaccharide fraction (Example 2.2) was analyzed according to Evaluation Method D. After 0, 5, 10, 20, and 30 minutes, samples (2 x 250 μl) from each mixture were transferred to test tubes on ice. An incubation mixture without added octasaccharide fraction was used as a control. The results are shown in Table 4 below; they show that the octasaccharide has the ability to inhibit Fxa in solution.
[0259] Example 5: Anti-FIIa activity; effect of Example 2.2 (octasaccharide fraction) in solution The anti-FIIa activity of the octasaccharide fraction (Example 2.2) was analyzed according to the evaluation method E. The incubation mixture without the addition of octasaccharide fraction was used as a control. After 0, 5, 10, 20, and 30 minutes, duplicate samples (250 μl) from each mixture were transferred to test tubes on ice. At the end of the incubation period, the residual FIIa activity was measured by adding FIIa substrate (final concentration 0.25 mM). The enzyme activity decreased at the same rate in the presence and absence of the octasaccharide fraction, indicating that the octasaccharide at the tested concentration has no catalytic effect on AT-mediated FIIa inhibition. See Table 4 below. [Table 4] Table 4. Effect of Example 2.2 (Octasaccharide) in solution on the inhibition of FXa and FIIa in the presence of AT. Control is incubation mixture without octasaccharide. ND=not determined. * Analyzed immediately before the addition of the octasaccharide, ** Analyzed immediately after addition of the octasaccharide
[0260] It can therefore be noted that the octasaccharide fraction, when in solution, does not show any obvious catalytic effect on AT-mediated FIIa inhibition.
[0261] Example 6: Immobilization of heparin fragments onto layer-by-layer coatings on surfaces (General coating process) The luminal surface of a piece of PVC tubing was coated with a layer-by-layer coating of cationic and anionic polymers essentially using the method described in Larm et al. in EP0086186A1, EP0495820B1, and EP0086187A1 (all of which are fully incorporated herein by reference). Specifically, the luminal surface of the tubing was first cleaned with isopropanol and an oxidizing agent. The coating bilayer was created by layer-by-layer adsorption of a cationic polymer (polyamine, 0.05 g / L in water) and an anionic polymer (dextran sulfate, 0.1 g / L in water). The polyamine was cross-linked with a bifunctional aldehyde (crotonaldehyde).
[0262] The anionic polymer is dextran sulfate having a MW of 4000 kDa as measured according to Evaluation Method K and a high charge density (6.2 μeq / g) as measured according to Evaluation Method L. The dextran sulfate was added to a high salt solution (NaCl, 1.7 M).
[0263] Example 6.1: Immobilization of Octasaccharide PVC tubing (ID 3 mm) was coated with 16 ml of the "Octa" fraction (Example 2.2) diluted with 84 ml of 0.05M NaCl according to the general procedure described above, and the Octa fraction was then immobilized on the outermost layer of polyamine via reductive amination essentially as described in Larm et al. in EP0086186A1 and EP0495820B1.
[0264] Example 6.2: Immobilization of Heparin (Positive Control) PVC tubing (ID 3 mm) was coated with heparin prepared as described in EP0086186 and US 6,461,665 according to the general procedure described above. The heparin has a dispersed molecular weight distribution with an average heparin chain length greater than 18 sugar units and therefore has the ability to inhibit both FXa and FIIa in solution. Heparin was attached to the outermost layer of polyamine on the PVC tubing via reductive amination as carried out for Example 6.1 above.
[0265] Example 6.3: Immobilization of a synthetic pentasaccharide with a linker, Example 1.1 Example 1.1 is reacted with commercially available N-hydroxysuccinimide ester of 6,6-dimethoxyhexanoic acid and then deprotected according to the procedure described in Pozsgay, J. Org. Chem., 63(17), 1998, 5983-5999. Aldehyde-functionalized spacers can be attached to the surface according to the general procedure described above. See FIG. 6.
[0266] Example 7: Immobilization of heparin fragments onto alternative layer-by-layer coatings on surfaces (General coating process) The following process was essentially the same as that described in Example 6. In this case, the cationic polymer used was Epomin P-1050 (Nippon Shokubai, 70 kDa) and the anionic polymer used was dextran sulfate (Tdb Consultancy) with a low charge density (3 μeq / g) as measured according to evaluation method L. Dextran sulfate was applied at a salt concentration of either 0.25 or 0.5 M.
[0267] Example 7.1: Immobilization of Octasaccharide PVC tubing (ID 3 mm) was coated according to the general procedure described above, where dextran sulfate was applied at a NaCl concentration of 0.25 M. The octasaccharide fraction (Example 2.2) was then immobilized on the outermost layer of polyamines via reductive amination as described in Example 6.1.
[0268] Example 7.2: Immobilization of Octasaccharides Using Higher Salt Concentrations PVC tubing (ID 3 mm) was coated according to the general procedure described in Example 7.1 above, where dextran sulfate was applied at a NaCl concentration of 0.50 M.
[0269] Example 8: Evaluation of PVC tubing coated with heparin fragments by toluidine staining PVC tubing coated according to Examples 6.1, 7.1, and 7.2 were subjected to the Toluidine Blue staining test set forth in Evaluation Method I. An intense blue / violet color was observed on the luminal surface of the tubing, indicating extensive covalent attachment of heparin fragments. The uniform staining observed on the tested tubing indicates the formation of a uniform coating. See FIG. 8.
[0270] Example 9: Evaluation of Heparin Density of PVC Tubing Coated with Heparin Fragments The heparin densities of Examples 6.1, 6.2, 7.1, and 7.2 were determined by Evaluation Method H. The results are shown in Table 5 below.
[0271] Example 10: Evaluation of heparin activity of PVC tubing coated with heparin fragments The heparin activity of the octasaccharide-coated surfaces described in Examples 6.1, 7.1, and 7.2 was determined by Evaluation Method J; heparin-coated PVC tubing (Example 6.2) was used as a positive control. Heparin activity (pmol AT / cm) of Example 6.2 2 ) was considered as 100% activity and the activity of the other coated surfaces was expressed relative to this. The results are shown in Table 5 below. [Table 5] Table 5. Evaluation of octasaccharide-coated surfaces described in Examples 6 and 7
[0272] Although the heparin density values for the octasaccharide coatings (Examples 6.1, 7.1, and 7.2) and the heparin coating (Example 6.2) were similar, the AT-binding capacity (heparin activity; "HA") of the octasaccharide coating was lower compared to the heparin coating. However, this is expected given the relatively low anti-FXa activity exhibited by the octasaccharide fraction in solution (Example 2.2 in Table 3). Thus, the octasaccharide fragment appears to substantially retain its AT-binding capacity after immobilization.
[0273] Example 11: Evaluation of anti-FXa activity of PVC tubing coated with heparin fragments The anti-FXa activity of PVC tubing coated according to Example 6.1 was evaluated according to Evaluation Method F, using Example 6.2 as a positive control. The results are shown in Table 6 below. [Table 6] Table 6. Inhibition of FXa in octasaccharide coated and uncoated tubing loops + test tube control. In contrast to uncoated PVC and test tube controls, the coated surfaces catalyzed rapid inhibition of FXa.
[0274] From Table 6 it can be seen that the various examples performed as expected. The octasaccharide coated surface was effective in catalyzing the inhibition of FXa - and this property is therefore maintained whether the octasaccharide is immobilized or in solution (see Example 5, Table 4). The uncoated plain PVC loop control and the test tube control were ineffective in catalyzing the inhibition of FXa.
[0275] Also, as expected, the heparin-coated positive control (Example 6.2), having an average heparin chain length substantially greater than 18 sugar units, was able to effectively inhibit FXa when immobilized (residual FXa activity 1.4 mOD / min, 99% inhibition of FXa activity).
[0276] Example 12: Evaluation of anti-FIIa activity of PVC tubing coated with heparin fragments Loops of PVC tubing coated according to Examples 6.1, 6.2, 7.1, and 7.2 were evaluated according to Evaluation Method G. As a positive control, the same reaction mixture was incubated in PVC tubing coated with heparin (Example 6.2, where the average heparin chain length is substantially greater than 18 sugar units and therefore this coating is believed to inhibit both FXa and FIIa in solution). The results are shown in Table 7. [Table 7] Table 7. Inhibition of FIIa in octasaccharide coated and uncoated tubing loops + test tube control. Results are normalized to uncoated PVC tubing.
[0277] The results show that these heparin fragments, which lack the ability to catalyze the inhibition of FIIa by AT in solution, are surprisingly able to catalyze this same reaction when immobilized on a surface. The immobilized fragments are organized in a manner that may enable them to act synergistically to accomplish what would require much longer molecules in solution.
[0278] This effect can be seen in all octasaccharide coated examples (6.1, 7.1, 7.2), however the coating used in example 6.1 shows higher inhibition compared to examples 7.1 and 7.2.
[0279] As expected, the heparin-coated positive control (Example 6.2), having an average heparin chain length substantially greater than 18 sugar units, was able to effectively inhibit FIIa when immobilized (residual FIIa activity 1.4 mOD / min, 99% inhibition of FIIa activity).
[0280] Throughout this specification and the claims which follow, unless the context otherwise requires, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer, step, group of integers, or group of steps, but not the exclusion of any other integer, step, group of integers, or group of steps.
[0281] All patents and patent applications mentioned herein are incorporated by reference in their entirety. The present application provides the following aspects of the invention. (Aspect 1) 1. An anticoagulant surface, the surface having a plurality of heparin fragments covalently attached thereto, wherein the fragments consist of 5 to 18 saccharide units, and at least a portion of the plurality of fragments has polysaccharide sequence A: (chemical 1) TIFF0007584404000127.tif39170 (Wherein, R=Ac or SO 3 - is) Including, The anticoagulant surface, which surface catalyzes the inhibition of FIIa and FXa by AT. (Aspect 2) The surface of embodiment 1, wherein said surface inhibits FIIa activity by at least 50% when measured according to evaluation method G. (Aspect 3) The surface of any of embodiments 1 or 2, wherein said surface inhibits FXa activity by at least 50% when measured according to Evaluation Method F. (Aspect 4) The surface according to any one of embodiments 1 to 3, wherein the structure of the heparin fragment is heterogeneous. (Aspect 5) The surface according to any one of embodiments 1 to 3, wherein the heparin fragments have a uniform structure and all contain the polysaccharide sequence A. (Aspect 6) The surface of any one of embodiments 1-5, wherein the fragment of heparin is a fragment of native heparin produced by a process comprising degrading native heparin. (Aspect 7) The surface of any one of embodiments 1 to 5, wherein the fragment of heparin is synthetically produced. (Aspect 8) The surface according to any one of embodiments 1 to 7, wherein the fragment of heparin is covalently attached to the surface via a linker. (Aspect 9) The surface of embodiment 8, wherein the linker comprises a thioether or a 1,2,3-triazole. (Aspect 10) 10. The surface of any of embodiments 8 or 9, wherein a spacer is positioned between said linker and said surface. (Aspect 11) The surface of any one of embodiments 1-10, wherein the fragment of heparin is single-point attached. (Aspect 12) 12. The surface of embodiment 11, wherein the fragments of heparin are end point attached. (Aspect 13) 13. The surface of embodiment 12, wherein the heparin fragment is covalently attached to the surface via its reducing end. (Aspect 14) 14. The surface of embodiment 13, wherein the heparin fragment is covalently attached to the surface via position C1 of its reducing end. (Aspect 15) 15. The surface of any of embodiments 13 or 14, wherein the surface comprises an amine group that reacts with the reducing end of the heparin fragment. (Aspect 16) At least 1 pmol / surface cm for binding of AT, as suitably measured according to Evaluation Method J 2 , e.g., at least 2 pmol / cm of surface 2 , at least 3 pmol / surface cm 2 , at least 4 pmol / surface cm 2 , or at least 5 pmol / cm of surface 2 16. The surface according to any one of embodiments 1 to 15, having a heparin activity of (Aspect 17) At least 1 μg / cm when suitably measured according to Evaluation Method H 2 , e.g., at least 2 μg / cm2 , at least 4 μg / cm 2 , at least 5 μg / cm 2 , or at least 6 μg / cm 2 17. The surface according to any one of embodiments 1 to 16, having a heparin concentration of (Aspect 18) The surface according to any one of embodiments 1 to 17, wherein the fragment of heparin consists of at least 6 sugar units. (Aspect 19) The surface according to any one of embodiments 1 to 18, wherein the heparin fragment consists of 16 sugar units or less. (Aspect 20) 20. The surface of embodiment 19, wherein the heparin fragment consists of 14 or fewer sugar units. (Aspect 21) 21. The surface of embodiment 20, wherein the fragment of heparin consists of 10 sugar units or less. (Aspect 22) 18. The surface according to any one of embodiments 1 to 17, wherein the heparin fragment consists of five sugar units. (Aspect 23) The surface of any one of embodiments 1 to 9 or 11 to 22, wherein the heparin fragment is not covalently attached to the surface via a thioether-containing linker or a 1,2,3-triazole-containing linker. (Aspect 24) 24. The surface of embodiment 23, wherein said heparin fragment is not covalently attached to said surface via any linker. (Aspect 25) The heparin fragment is covalently attached to the surface via a linker, the linker being represented by formula (I): (II) (CH 2 ) n NHCO(CH 2 ) m (In the formula, n is 1 to 20, and m is 1 to 20.) The surface of any one of embodiments 1-9 or 11-24, comprising: (Aspect 26) 26. The surface of embodiment 25, wherein n is 5 and m is 4. (Aspect 27) A solid object comprising the surface according to any one of embodiments 1 to 26. (Aspect 28) 28. The solid object of embodiment 27, wherein the surface comprises a layer by layer coating, the outer coating layer being a cationic polymer to which the fragments of heparin are covalently attached. (Aspect 29) 29. The solid object of embodiment 28, wherein the layers of the layer coating are alternating layers of cationic and anionic polymers. (Aspect 30) 30. The solid object of any of claims 28 or 29, wherein the cationic polymer layer is a layer of a cationic polymeric amine. (Aspect 31) 31. The solid object according to any of embodiments 29 or 30, wherein said anionic polymer layer is a layer of dextran sulfate. (Aspect 32) The solid object of any one of embodiments 27 to 31, which is a medical device.
Claims
1. 1. A solid object comprising an anticoagulant surface, said surface having covalently attached thereto a plurality of fragments of heparin, wherein said fragments consist of 6 to 18 saccharide units, and at least a portion of said plurality of fragments have the polysaccharide sequence A: 【Chemistry 1】 (Wherein, R=Ac or SO 3 - is) Including, the surface catalyzes the inhibition of FIIa and FXa by AT; the heparin fragment is end-point linked; and The surface has at least 1 μg / cm 2 The solid object having a heparin fragment concentration of
2. 2. The solid object of claim 1, wherein the surface inhibits FIIa activity by at least 50% when measured according to evaluation method G.
3. 3. The solid object of claim 1, wherein the surface inhibits FXa activity by at least 50% when measured according to evaluation method F.
4. The solid object according to any one of claims 1 to 3, wherein the structure of the heparin fragment is heterogeneous.
5. The solid object according to any one of claims 1 to 3, wherein the structure of said heparin fragments is uniform and all contain the polysaccharide sequence A.
6. The solid object of any one of claims 1 to 5, wherein the fragment of heparin is a fragment of native heparin produced by a process comprising degrading native heparin.
7. The solid object of any one of claims 1 to 5, wherein the fragment of heparin is synthetically produced.
8. The solid object of any one of claims 1 to 7, wherein the fragment of heparin is covalently attached to the surface via a linker.
9. 9. The solid object of claim 8, wherein the linker comprises a thioether or a 1,2,3-triazole.
10. 10. The solid object of claim 8 or 9, wherein a spacer is positioned between the linker and the surface.
11. The solid object according to any one of claims 1 to 10, wherein the heparin fragment is covalently attached to the surface via its reducing end.
12. The solid object of claim 11, wherein the heparin fragment is covalently attached to the surface via position C1 of its reducing end.
13. 13. The solid object of claim 11 or 12, wherein the surface comprises an amine group that reacts with the reducing end of the heparin fragment.
14. The surface has at least 1 pmol / cm of surface for binding of AT, as suitably measured according to Evaluation Method J. 2 , e.g., at least 2 pmol / cm of surface 2 , at least 3 pmol / surface cm 2 , at least 4 pmol / surface cm 2 , or at least 5 pmol / cm of surface 2 The solid object according to any one of claims 1 to 13, having a heparin activity of 0.1 to 0.5%.
15. The surface preferably has a surface area of at least 2 μg / cm when measured according to Evaluation Method H. 2 , at least 4 μg / cm 2 , at least 5 μg / cm 2 , or at least 6 μg / cm 2 The solid object of any one of claims 1 to 14, having a heparin concentration of
16. The solid object according to any one of claims 1 to 15, wherein the fragment of heparin consists of 16 sugar units or less.
17. 17. The solid object of claim 16, wherein the fragment of heparin consists of 14 sugar units or less.
18. 18. The solid object of claim 17, wherein the fragment of heparin consists of 10 sugar units or less.
19. The solid object of any one of claims 1 to 8 or 10 to 18, wherein the heparin fragment is not covalently attached to the surface via a thioether-containing linker or a 1,2,3-triazole-containing linker.
20. 20. The solid object of claim 19, wherein the heparin fragment is not covalently attached to the surface via any linker.
21. The heparin fragment is covalently attached to the surface via a linker, the linker being represented by formula (I): (I) (CH 2 ) n NHCO(CH 2 ) m (wherein n is 1 to 20 and m is 1 to 20).
20. The solid object of any one of claims 1 to 9 or 11 to 19, comprising:
22. 22. The solid object of claim 21, wherein n is 5 and m is 4.
23. 23. The solid object of any one of claims 1 to 22, wherein said surface comprises a layer by layer coating, an outer coating layer being a cationic polymer to which said heparin fragments are covalently attached.
24. 24. The solid object of claim 23, wherein the layers of the layer coating are alternating layers of cationic and anionic polymers.
25. 25. The solid object of claim 23 or 24, wherein the cationic polymer layer is a layer of a cationic polymeric amine.
26. 26. The solid object of claim 24 or 25, wherein the anionic polymer layer is a layer of dextran sulfate.
27. The solid object of any one of claims 23 to 26, which is a medical device.
Citation Information
Patent Citations
Fixed biological entities
JP2012502678A
